{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "598f9a8b-c60b-42f7-911a-f3a4456c5885",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "df6a964e-0b85-442c-af12-8db273bdb26f",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.read_csv('covid.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "eed7713e-6cca-4ad6-b178-7fe624a07d2e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "  Age of the participants Gender of the participants  \\\n",
      "0             20-29 years                     female   \n",
      "1         Greater than 60                     Female   \n",
      "2             40-49 years                     Female   \n",
      "3               <20 years                       Male   \n",
      "4             20-29 years                       Male   \n",
      "\n",
      "  Religion of the participants Location of the participants  \\\n",
      "0                       Muslim                        Rural   \n",
      "1                       Muslim                        Urban   \n",
      "2                       Muslim                        Urban   \n",
      "3                       Muslim                        Urban   \n",
      "4                       Muslim                        Urban   \n",
      "\n",
      "  Nationality of the participants Division of the participants  \\\n",
      "0                     Bangladeshi                      Rangpur   \n",
      "1                     Bangladeshi                      Rangpur   \n",
      "2                     Bangladeshi                      Rangpur   \n",
      "3                     Bangladeshi                      Rangpur   \n",
      "4                     Bangladeshi                        Dhaka   \n",
      "\n",
      "  Occupation of the participants Education of the participants  \\\n",
      "0                        Student           University or above   \n",
      "1                       Employed              Higher Secondary   \n",
      "2                     House Wife              Higher Secondary   \n",
      "3                        Student                       Primary   \n",
      "4                        Student           University or above   \n",
      "\n",
      "  Health Status of the participants Have you received the COVID-19 vaccine?  \\\n",
      "0                              Good                                     Yes   \n",
      "1                              Good                                     Yes   \n",
      "2                              Good                                     Yes   \n",
      "3                              Good                                      No   \n",
      "4                         Excellent                                     Yes   \n",
      "\n",
      "   ... How severe were the symptoms?    How long did the symptoms last?   \\\n",
      "0  ...                         Moderate                         1-3 days   \n",
      "1  ...                              NaN                              NaN   \n",
      "2  ...                              NaN                              NaN   \n",
      "3  ...                              NaN                              NaN   \n",
      "4  ...                              NaN                              NaN   \n",
      "\n",
      "  Did you seek medical attention for these symptoms?   \\\n",
      "0                                                Yes    \n",
      "1                                                 No    \n",
      "2                                                 No    \n",
      "3                                                NaN    \n",
      "4                                                NaN    \n",
      "\n",
      "  If yes, what type of treatment did you receive?   \\\n",
      "0                          Prescription medication   \n",
      "1                                              NaN   \n",
      "2                                              NaN   \n",
      "3                                              NaN   \n",
      "4                                              NaN   \n",
      "\n",
      "  Did these symptoms resolve completely?  \\\n",
      "0                                     No   \n",
      "1                                    NaN   \n",
      "2                                    NaN   \n",
      "3                                    NaN   \n",
      "4                                    NaN   \n",
      "\n",
      "  Did these dermatological side effects affect your daily activities?   \\\n",
      "0                                                Yes                     \n",
      "1                                                 No                     \n",
      "2                                                 No                     \n",
      "3                                                NaN                     \n",
      "4                                                NaN                     \n",
      "\n",
      "  If yes, specify how they impacted you  \\\n",
      "0                       Other (Specify)   \n",
      "1                                   NaN   \n",
      "2                                   NaN   \n",
      "3                                   NaN   \n",
      "4                                   NaN   \n",
      "\n",
      "  Do you believe the COVID-19 vaccine caused or worsened your skin symptoms?   \\\n",
      "0                                                Yes                            \n",
      "1                                                 No                            \n",
      "2                                                 No                            \n",
      "3                                                NaN                            \n",
      "4                                                NaN                            \n",
      "\n",
      "  Do you have concerns about receiving future doses due to these side effects?   \\\n",
      "0                                                Yes                              \n",
      "1                                                 No                              \n",
      "2                                                 No                              \n",
      "3                                                NaN                              \n",
      "4                                                NaN                              \n",
      "\n",
      "   Would you recommend COVID-19 vaccination to others despite these side effects?   \n",
      "0                                                 No                                \n",
      "1                                                 No                                \n",
      "2                                                 No                                \n",
      "3                                                NaN                                \n",
      "4                                                NaN                                \n",
      "\n",
      "[5 rows x 34 columns]\n",
      "    Age of the participants Gender of the participants  \\\n",
      "0               20-29 years                     female   \n",
      "1           Greater than 60                     Female   \n",
      "2               40-49 years                     Female   \n",
      "3                 <20 years                       Male   \n",
      "4               20-29 years                       Male   \n",
      "..                      ...                        ...   \n",
      "810             30-39 years                     Female   \n",
      "811             30-39 years                     Female   \n",
      "812             30-39 years                       Male   \n",
      "813             20-29 years                       Male   \n",
      "814             20-29 years                     Female   \n",
      "\n",
      "    Religion of the participants Location of the participants  \\\n",
      "0                         Muslim                        Rural   \n",
      "1                         Muslim                        Urban   \n",
      "2                         Muslim                        Urban   \n",
      "3                         Muslim                        Urban   \n",
      "4                         Muslim                        Urban   \n",
      "..                           ...                          ...   \n",
      "810                       Muslim                        Urban   \n",
      "811                        Other                        Urban   \n",
      "812                        Hindu                        Urban   \n",
      "813                        Other                        Rural   \n",
      "814                       Muslim                        Other   \n",
      "\n",
      "    Nationality of the participants Division of the participants  \\\n",
      "0                       Bangladeshi                      Rangpur   \n",
      "1                       Bangladeshi                      Rangpur   \n",
      "2                       Bangladeshi                      Rangpur   \n",
      "3                       Bangladeshi                      Rangpur   \n",
      "4                       Bangladeshi                        Dhaka   \n",
      "..                              ...                          ...   \n",
      "810                     Bangladeshi                      Rangpur   \n",
      "811                     Bangladeshi                      Rangpur   \n",
      "812                     Bangladeshi                      Rangpur   \n",
      "813                     Bangladeshi                       Khulna   \n",
      "814                     Bangladeshi                       Khulna   \n",
      "\n",
      "    Occupation of the participants Education of the participants  \\\n",
      "0                          Student           University or above   \n",
      "1                         Employed              Higher Secondary   \n",
      "2                       House Wife              Higher Secondary   \n",
      "3                          Student                       Primary   \n",
      "4                          Student           University or above   \n",
      "..                             ...                           ...   \n",
      "810                       Employed           University or above   \n",
      "811                       Employed              Higher Secondary   \n",
      "812                       Employed           University or above   \n",
      "813                        Student           University or above   \n",
      "814                        Student           University or above   \n",
      "\n",
      "    Health Status of the participants Have you received the COVID-19 vaccine?  \\\n",
      "0                                Good                                     Yes   \n",
      "1                                Good                                     Yes   \n",
      "2                                Good                                     Yes   \n",
      "3                                Good                                      No   \n",
      "4                           Excellent                                     Yes   \n",
      "..                                ...                                     ...   \n",
      "810                              Poor                                     Yes   \n",
      "811                              Good                                     Yes   \n",
      "812                              Good                                      No   \n",
      "813                              Good                                     Yes   \n",
      "814                              Good                                     Yes   \n",
      "\n",
      "     ... How severe were the symptoms?    How long did the symptoms last?   \\\n",
      "0    ...                         Moderate                         1-3 days   \n",
      "1    ...                              NaN                              NaN   \n",
      "2    ...                              NaN                              NaN   \n",
      "3    ...                              NaN                              NaN   \n",
      "4    ...                              NaN                              NaN   \n",
      "..   ...                              ...                              ...   \n",
      "810  ...                         Moderate                         1-3 days   \n",
      "811  ...                           Severe                         1-3 days   \n",
      "812  ...                           Severe                         1-3 days   \n",
      "813  ...                         Moderate                         1-3 days   \n",
      "814  ...                         Moderate                 More than a week   \n",
      "\n",
      "    Did you seek medical attention for these symptoms?   \\\n",
      "0                                                  Yes    \n",
      "1                                                   No    \n",
      "2                                                   No    \n",
      "3                                                  NaN    \n",
      "4                                                  NaN    \n",
      "..                                                 ...    \n",
      "810                                                Yes    \n",
      "811                                                Yes    \n",
      "812                                                 No    \n",
      "813                                                Yes    \n",
      "814                                                 No    \n",
      "\n",
      "    If yes, what type of treatment did you receive?   \\\n",
      "0                            Prescription medication   \n",
      "1                                                NaN   \n",
      "2                                                NaN   \n",
      "3                                                NaN   \n",
      "4                                                NaN   \n",
      "..                                               ...   \n",
      "810                      Over-the-counter medication   \n",
      "811                      Over-the-counter medication   \n",
      "812                      Over-the-counter medication   \n",
      "813                          Prescription medication   \n",
      "814                          Prescription medication   \n",
      "\n",
      "    Did these symptoms resolve completely?  \\\n",
      "0                                       No   \n",
      "1                                      NaN   \n",
      "2                                      NaN   \n",
      "3                                      NaN   \n",
      "4                                      NaN   \n",
      "..                                     ...   \n",
      "810                                     No   \n",
      "811                                     No   \n",
      "812                                     No   \n",
      "813                                     No   \n",
      "814                                     No   \n",
      "\n",
      "    Did these dermatological side effects affect your daily activities?   \\\n",
      "0                                                  Yes                     \n",
      "1                                                   No                     \n",
      "2                                                   No                     \n",
      "3                                                  NaN                     \n",
      "4                                                  NaN                     \n",
      "..                                                 ...                     \n",
      "810                                                Yes                     \n",
      "811                                                Yes                     \n",
      "812                                                Yes                     \n",
      "813                                                Yes                     \n",
      "814                                                Yes                     \n",
      "\n",
      "                 If yes, specify how they impacted you  \\\n",
      "0                                      Other (Specify)   \n",
      "1                                                  NaN   \n",
      "2                                                  NaN   \n",
      "3                                                  NaN   \n",
      "4                                                  NaN   \n",
      "..                                                 ...   \n",
      "810     Work or school performance;Social interactions   \n",
      "811  Work or school performance;Social interactions...   \n",
      "812  Work or school performance;Social interactions...   \n",
      "813     Work or school performance;Social interactions   \n",
      "814     Work or school performance;Social interactions   \n",
      "\n",
      "    Do you believe the COVID-19 vaccine caused or worsened your skin symptoms?   \\\n",
      "0                                                  Yes                            \n",
      "1                                                   No                            \n",
      "2                                                   No                            \n",
      "3                                                  NaN                            \n",
      "4                                                  NaN                            \n",
      "..                                                 ...                            \n",
      "810                                                Yes                            \n",
      "811                                                Yes                            \n",
      "812                                                Yes                            \n",
      "813                                                Yes                            \n",
      "814                                                Yes                            \n",
      "\n",
      "    Do you have concerns about receiving future doses due to these side effects?   \\\n",
      "0                                                  Yes                              \n",
      "1                                                   No                              \n",
      "2                                                   No                              \n",
      "3                                                  NaN                              \n",
      "4                                                  NaN                              \n",
      "..                                                 ...                              \n",
      "810                                                Yes                              \n",
      "811                                                Yes                              \n",
      "812                                                Yes                              \n",
      "813                                                Yes                              \n",
      "814                                                Yes                              \n",
      "\n",
      "     Would you recommend COVID-19 vaccination to others despite these side effects?   \n",
      "0                                                   No                                \n",
      "1                                                   No                                \n",
      "2                                                   No                                \n",
      "3                                                  NaN                                \n",
      "4                                                  NaN                                \n",
      "..                                                 ...                                \n",
      "810                                                 No                                \n",
      "811                                                 No                                \n",
      "812                                                 No                                \n",
      "813                                                 No                                \n",
      "814                                                 No                                \n",
      "\n",
      "[815 rows x 34 columns]\n"
     ]
    }
   ],
   "source": [
    "print(df.head())\n",
    "print(df)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "72fa222e-58e1-42bb-8c9f-3bbecda0bfb2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Variable: Age of the participants\n",
      "Age of the participants  Frequency Percent\n",
      "            20-29 years        378   46.4%\n",
      "            30-39 years        171   21.0%\n",
      "            40-49 years        106   13.0%\n",
      "              <20 years         96   11.8%\n",
      "            50-59 years         46    5.6%\n",
      "        Greater than 60         18    2.2%\n",
      "\n",
      "Variable: Gender of the participants\n",
      "Gender of the participants  Frequency Percent\n",
      "                    Female        413   50.7%\n",
      "                      Male        401   49.2%\n",
      "                    female          1    0.1%\n",
      "\n",
      "Variable: Religion of the participants\n",
      "Religion of the participants  Frequency Percent\n",
      "                      Muslim        687   84.3%\n",
      "                       Hindu        115   14.1%\n",
      "                       Other         13    1.6%\n",
      "\n",
      "Variable: Location of the participants\n",
      "Location of the participants  Frequency Percent\n",
      "                       Urban        413   50.7%\n",
      "                       Rural        387   47.5%\n",
      "                       Other         15    1.8%\n",
      "\n",
      "Variable: Nationality of the participants\n",
      "Nationality of the participants  Frequency Percent\n",
      "                    Bangladeshi        809   99.3%\n",
      "                       Somalian          3    0.4%\n",
      "                         Nepali          2    0.2%\n",
      "                           Duna          1    0.1%\n",
      "\n",
      "Variable: Division of the participants\n",
      "Division of the participants  Frequency Percent\n",
      "                     Rangpur        530   65.0%\n",
      "                      Khulna        161   19.8%\n",
      "                       Dhaka        124   15.2%\n",
      "\n",
      "Variable: Occupation of the participants\n",
      "Occupation of the participants  Frequency Percent\n",
      "                       Student        411   50.4%\n",
      "                      Employed        253   31.0%\n",
      "                    Unemployed         94   11.5%\n",
      "                    House Wife         57    7.0%\n",
      "\n",
      "Variable: Education of the participants\n",
      "Education of the participants  Frequency Percent\n",
      "          University or above        481   59.0%\n",
      "             Higher Secondary        155   19.0%\n",
      "                    Secondary         97   11.9%\n",
      "                      Primary         79    9.7%\n",
      "                No education           3    0.4%\n",
      "\n",
      "Variable: Health Status of the participants\n",
      "Health Status of the participants  Frequency Percent\n",
      "                             Good        680   83.4%\n",
      "                             Poor        100   12.3%\n",
      "                        Excellent         35    4.3%\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Clean column names\n",
    "df.columns = df.columns.str.strip()\n",
    "\n",
    "# Categorical columns\n",
    "categorical_columns = [\n",
    "    'Age of the participants',\n",
    "    'Gender of the participants',\n",
    "    'Religion of the participants',\n",
    "    'Location of the participants',\n",
    "    'Nationality of the participants',\n",
    "    'Division of the participants',\n",
    "    'Occupation of the participants',\n",
    "    'Education of the participants',\n",
    "    'Health Status of the participants'\n",
    "]\n",
    "\n",
    "# Frequency and percentage table\n",
    "for col in categorical_columns:\n",
    "    print(f\"\\nVariable: {col}\")\n",
    "    freq_table = df[col].value_counts(dropna=False).reset_index()\n",
    "    freq_table.columns = [col, 'Frequency']\n",
    "    freq_table['Percent'] = (freq_table['Frequency'] / freq_table['Frequency'].sum()) * 100\n",
    "    print(freq_table.to_string(index=False, formatters={'Percent': '{:,.1f}%'.format}))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 174,
   "id": "7a8552d7-8250-4045-8799-3d4aca0a9969",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "\n",
    "df = pd.read_csv('covid.csv')\n",
    "\n",
    "\n",
    "vaccine_data = {\n",
    "    'Vaccine Name': [\"Don't Know The Name\", \"Sinovac\", \"Sinopharm\", \"Moderna\", \"Pfizer\", \"AstraZeneca\"],\n",
    "    'Rural': [80, 20, 60, 70, 90, 50],\n",
    "    'Urban': [120, 10, 40, 50, 110, 30]\n",
    "}\n",
    "\n",
    "# Create a DataFrame\n",
    "df = pd.DataFrame(vaccine_data)\n",
    "\n",
    "# Set the positions and width for the bars\n",
    "bar_width = 0.35\n",
    "index = range(len(df['Vaccine Name']))\n",
    "\n",
    "# Plotting the grouped bar chart\n",
    "fig, ax = plt.subplots(figsize=(10, 6))\n",
    "\n",
    "bar1 = ax.bar(index, df['Rural'], bar_width, label='Rural', color='#2c3e50')\n",
    "bar2 = ax.bar([i + bar_width for i in index], df['Urban'], bar_width, label='Urban', color='#27ae60')\n",
    "\n",
    "# Customize the plot\n",
    "ax.set_xlabel('Vaccine Name')\n",
    "ax.set_ylabel('Number of Vaccinations')\n",
    "ax.set_title('Distribution of Vaccines over Residence Type')\n",
    "ax.set_xticks([i + bar_width/2 for i in index])\n",
    "ax.set_xticklabels(df['Vaccine Name'], rotation=45, ha='right')\n",
    "ax.legend()\n",
    "\n",
    "# Adjust layout to prevent label cutoff\n",
    "plt.tight_layout()\n",
    "\n",
    "# Display the plot\n",
    "plt.savefig('residence_bar_chart.png')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "4b803ef9-dc90-4b20-a3d5-0fc0725bc4b8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Variable: Have you received the COVID-19 vaccine?\n",
      "Have you received the COVID-19 vaccine?  Frequency Percent\n",
      "                                    Yes        797   97.8%\n",
      "                                     No         18    2.2%\n",
      "\n",
      "Variable: Which vaccine did you receive?\n",
      "Which vaccine did you receive?  Frequency Percent\n",
      "                        Pfizer        241   29.6%\n",
      "                       Moderna        168   20.6%\n",
      "           Don't Know the name        140   17.2%\n",
      "                     Sinopharm        138   16.9%\n",
      "                   AstraZeneca        114   14.0%\n",
      "                       Sinovac         14    1.7%\n",
      "\n",
      "Variable: How many doses have you received?\n",
      "How many doses have you received?  Frequency Percent\n",
      "                                2        382   46.9%\n",
      "                                3        338   41.5%\n",
      "                                1         77    9.4%\n",
      "                             More         13    1.6%\n",
      "                              NaN          5    0.6%\n",
      "\n",
      "Variable: Did you experience any immediate side effects (within 24 hours) after vaccination?\n",
      "Did you experience any immediate side effects (within 24 hours) after vaccination?  Frequency Percent\n",
      "                                                                                No        404   49.6%\n",
      "                                                                               Yes        400   49.1%\n",
      "                                                                               NaN         11    1.3%\n",
      "\n",
      "Variable: If yes, specify the symptoms\n",
      "                                                                                  If yes, specify the symptoms  Frequency Percent\n",
      "                                                                                                           NaN        349   42.8%\n",
      "                                                                                                         Fever        109   13.4%\n",
      "                                                                                                          Pain         73    9.0%\n",
      "                                                                                                    Fever;Pain         69    8.5%\n",
      "                                                                                           Fever;Headache;Pain         30    3.7%\n",
      "                                                                                                      Headache         15    1.8%\n",
      "                                                                                   Fever;Fatigue;Headache;Pain         12    1.5%\n",
      "                                                                                            Fever;Fatigue;Pain         12    1.5%\n",
      "                                                                                                Fever;Headache         11    1.3%\n",
      "                                                                                                       Anxiety          6    0.7%\n",
      "                                                                                              Loss of appetite          5    0.6%\n",
      "                                                                                            Low blood pressure          5    0.6%\n",
      "                                                                             Headache;Loss of appetite;Anxiety          4    0.5%\n",
      "                                                                                             Hyper sensitivity          4    0.5%\n",
      "                                                                   Fatigue;Loss of appetite;Low blood pressure          4    0.5%\n",
      "                                                                                   Fever;Headache;Pain;Anxiety          3    0.4%\n",
      "                                                                               Fatigue;Pain;Low blood pressure          3    0.4%\n",
      "                                                                                                 Fever;Fatigue          3    0.4%\n",
      "                                                                          Fever;Headache;Pain;Loss of appetite          3    0.4%\n",
      "                                                                              Pain;High blood pressure;Anxiety          3    0.4%\n",
      "                                                         Fever;Fatigue;Headache;Pain;Anxiety;Hyper sensitivity          3    0.4%\n",
      "                                                                                                  Fatigue;Pain          3    0.4%\n",
      "                                                                                                            No          3    0.4%\n",
      "                                                                                                 Headache;Pain          2    0.2%\n",
      "                                                                   Headache;Loss of appetite;Hyper sensitivity          2    0.2%\n",
      "                                                                                                       Fatigue          2    0.2%\n",
      "                                                                    Pain;High blood pressure;Hyper sensitivity          2    0.2%\n",
      "                                                                                        Fever;Fatigue;Headache          2    0.2%\n",
      "                                                                                                  Pain;Anxiety          2    0.2%\n",
      "                                                                          Headache;High blood pressure;Anxiety          2    0.2%\n",
      "                                                                              Fatigue;Pain;High blood pressure          2    0.2%\n",
      "                                                                                           High blood pressure          2    0.2%\n",
      "                                                                                     Fever;High blood pressure          2    0.2%\n",
      "                                                                                              Headache;Anxiety          2    0.2%\n",
      "                                                                      Fever;Headache;Anxiety;Hyper sensitivity          2    0.2%\n",
      "                                                                       Fever;Headache;Loss of appetite;Anxiety          2    0.2%\n",
      "                                     Fever;Fatigue;Headache;Pain;High blood pressure;Anxiety;Hyper sensitivity          2    0.2%\n",
      "                                            Fever;Fatigue;Headache;Pain;High blood pressure;Low blood pressure          2    0.2%\n",
      "                                              Fever;Headache;Pain;Loss of appetite;High blood pressure;Anxiety          2    0.2%\n",
      "                                                                                Fever;Pain;High blood pressure          1    0.1%\n",
      "                                                                       Fever;Headache;Pain;High blood pressure          1    0.1%\n",
      "                                                   Headache;Pain;High blood pressure;Anxiety;Hyper sensitivity          1    0.1%\n",
      "                                                                               Pain;Low blood pressure;Anxiety          1    0.1%\n",
      "                                                                           Fever;Fatigue;Headache;Pain;Anxiety          1    0.1%\n",
      "                                                                                     Headache;Loss of appetite          1    0.1%\n",
      "                                                        Fever;Fatigue;Headache;Pain;Low blood pressure;Anxiety          1    0.1%\n",
      "                                                             Fever;Loss of appetite;Low blood pressure;Anxiety          1    0.1%\n",
      "                                                                         Fever;Fatigue;Pain;Hyper sensitivity;          1    0.1%\n",
      "                                                                           Fever;Pain;Loss of appetite;Anxiety          1    0.1%\n",
      "                                                                  Headache;Loss of appetite;Low blood pressure          1    0.1%\n",
      "                                                                            Fever;Headache;High blood pressure          1    0.1%\n",
      "                                                                                     Loss of appetite;Anxiety;          1    0.1%\n",
      "                                         Fever;Fatigue;Headache;High blood pressure;Low blood pressure;Anxiety          1    0.1%\n",
      "                                                                          Loss of appetite;Low blood pressure;          1    0.1%\n",
      "                                                                           Headache;Low blood pressure;Anxiety          1    0.1%\n",
      "                                                                                    Fatigue;Low blood pressure          1    0.1%\n",
      "                                                     Fever;Fatigue;Pain;High blood pressure;Low blood pressure          1    0.1%\n",
      "                                                                          Fever;Pain;Anxiety;Hyper sensitivity          1    0.1%\n",
      "                                                                                 Fever;Pain;Low blood pressure          1    0.1%\n",
      "                                                                                      Pain;Low blood pressure;          1    0.1%\n",
      "                                                                                              Fatigue;Headache          1    0.1%\n",
      "                                        Fever;Fatigue;Headache;Pain;Loss of appetite;Anxiety;Hyper sensitivity          1    0.1%\n",
      "                                              Fever;Fatigue;Headache;Pain;Loss of appetite;High blood pressure          1    0.1%\n",
      "                                                                                                        alergy          1    0.1%\n",
      "                                                                                                  Skin problem          1    0.1%\n",
      "                                                                                                       Alargy           1    0.1%\n",
      "                                                                                  Fever;Pain;Hyper sensitivity          1    0.1%\n",
      "                                                                                          Fever;Headache;Pain;          1    0.1%\n",
      "Fever;Fatigue;Headache;Pain;Loss of appetite;High blood pressure;Low blood pressure;Anxiety;Hyper sensitivity;          1    0.1%\n",
      "                                                                                                      Allergy           1    0.1%\n",
      "                                                                                                       Nothing          1    0.1%\n",
      "                                                                Fever;Fatigue;Pain;High blood pressure;Anxiety          1    0.1%\n",
      "                                                                 Fever;Headache;Pain;Anxiety;Hyper sensitivity          1    0.1%\n",
      "                                                                                                        Acene           1    0.1%\n",
      "                                                                                      Fatigue;Headache;Anxiety          1    0.1%\n",
      "                                                                                         Fever;Fatigue;Anxiety          1    0.1%\n",
      "                                           Fatigue;Headache;Pain;High blood pressure;Anxiety;Hyper sensitivity          1    0.1%\n",
      "                                                            Pain;High blood pressure;Anxiety;Hyper sensitivity          1    0.1%\n",
      "                                                                 Fever;Fatigue;Headache;Pain;Hyper sensitivity          1    0.1%\n",
      "                                                                                Fever;Fatigue;Loss of appetite          1    0.1%\n",
      "                                                                                    Fever;Fatigue;Pain;Anxiety          1    0.1%\n",
      "                                                                                            I had no simptomps          1    0.1%\n",
      "                                                                                   Fever;Pain;Loss of appetite          1    0.1%\n",
      "                                                                                                    No symptom          1    0.1%\n",
      "                                                                                        Pain;Hyper sensitivity          1    0.1%\n",
      "                                                                                                 Pain;Anxiety;          1    0.1%\n",
      "                                                                        Fever;Fatigue;Pain;High blood pressure          1    0.1%\n",
      "                                                                                       Pain;Low blood pressure          1    0.1%\n",
      "                                                                         Headache;High blood pressure;Anxiety;          1    0.1%\n",
      "                                                                                          Fever; Headache;Pain          1    0.1%\n",
      "\n",
      "Variable: Have you taking any medicine after receiving vaccine?\n",
      "Have you taking any medicine after receiving vaccine?  Frequency Percent\n",
      "                                                   No        534   65.5%\n",
      "                                                  Yes        265   32.5%\n",
      "                                                  NaN         16    2.0%\n",
      "\n",
      "Variable: Did you admitted in hospital / ICU after taking vaccine?\n",
      "Did you admitted in hospital / ICU after taking vaccine?  Frequency Percent\n",
      "                                                      No        729   89.4%\n",
      "                                                     Yes         70    8.6%\n",
      "                                                     NaN         16    2.0%\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Clean column names\n",
    "df.columns = df.columns.str.strip()\n",
    "\n",
    "# Vaccine-related categorical variables\n",
    "vaccine_columns = [\n",
    "    'Have you received the COVID-19 vaccine?',\n",
    "    'Which vaccine did you receive?',\n",
    "    'How many doses have you received?',\n",
    "    'Did you experience any immediate side effects (within 24 hours) after vaccination?',\n",
    "    'If yes, specify the symptoms',\n",
    "    'Have you taking any medicine after receiving vaccine?',\n",
    "    'Did you admitted in hospital / ICU after taking vaccine?'\n",
    "]\n",
    "\n",
    "# Loop through and create frequency + percentage tables\n",
    "for col in vaccine_columns:\n",
    "    print(f\"\\nVariable: {col}\")\n",
    "    freq_table = df[col].value_counts(dropna=False).reset_index()\n",
    "    freq_table.columns = [col, 'Frequency']\n",
    "    freq_table['Percent'] = (freq_table['Frequency'] / freq_table['Frequency'].sum()) * 100\n",
    "    print(freq_table.to_string(index=False, formatters={'Percent': '{:,.1f}%'.format}))\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "81f887be-6f7e-40fb-8e6c-d6dc31774e2f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Variable: Do you have any pre-existing skin conditions?\n",
      "Do you have any pre-existing skin conditions?  Frequency Percent\n",
      "                                           No        617   75.7%\n",
      "                                          Yes        198   24.3%\n",
      "\n",
      "Variable: If yes, specify the condition(s)\n",
      "If yes, specify the condition(s)  Frequency Percent\n",
      "                             NaN        577   70.8%\n",
      "                          Eczema         64    7.9%\n",
      "                            Acne         54    6.6%\n",
      "                      Dermatitis         43    5.3%\n",
      "                       Psoriasis         42    5.2%\n",
      "                     Eczema;Acne          9    1.1%\n",
      "                              No          8    1.0%\n",
      "               Eczema;Dermatitis          6    0.7%\n",
      "                 Acne;Dermatitis          5    0.6%\n",
      "                Psoriasis;Eczema          3    0.4%\n",
      "                        Nothing           1    0.1%\n",
      "                 Psoriasis;Acne;          1    0.1%\n",
      "            Psoriasis;Dermatitis          1    0.1%\n",
      "          Eczema;Acne;Dermatitis          1    0.1%\n",
      "\n",
      "Variable: Are you currently undergoing treatment for any dermatological condition?\n",
      "Are you currently undergoing treatment for any dermatological condition?  Frequency Percent\n",
      "                                                                     Yes        440   54.0%\n",
      "                                                                      No        339   41.6%\n",
      "                                                                     NaN         36    4.4%\n",
      "\n",
      "Variable: If yes, specify the type of treatment\n",
      "                             If yes, specify the type of treatment  Frequency Percent\n",
      "                                                               NaN        338   41.5%\n",
      "        Topical (e.g., creams, ointments);Oral (e.g., antibiotics)        251   30.8%\n",
      "                                 Topical (e.g., creams, ointments)        118   14.5%\n",
      "                                          Oral (e.g., antibiotics)         76    9.3%\n",
      "                                                                No         13    1.6%\n",
      "Topical (e.g., creams, ointments);Oral (e.g., antibiotics);Shampoo          5    0.6%\n",
      "   Topical (e.g., creams, ointments);Oral (e.g., antibiotics);Soap          5    0.6%\n",
      "                                                          Nothing           1    0.1%\n",
      "                                                           Nothing          1    0.1%\n",
      "                                                          Natural           1    0.1%\n",
      "                                                       Homiopathy           1    0.1%\n",
      "                                            Oral(e.g., antibiotics          1    0.1%\n",
      "  Topical (e.g., creams, ointments);Oral (e.g., antibiotics);syrup          1    0.1%\n",
      "  Topical (e.g., creams, ointments);Oral (e.g., antibiotics);Syrup          1    0.1%\n",
      "                                         Oral (e.g., antibiotics);          1    0.1%\n",
      "  Topical (e.g., creams, ointments);Oral (e.g., antibiotics);Serum          1    0.1%\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Clean column names to avoid extra spaces\n",
    "df.columns = df.columns.str.strip()\n",
    "\n",
    "# Dermatology-related variables\n",
    "derm_columns = [\n",
    "    'Do you have any pre-existing skin conditions?',\n",
    "    'If yes, specify the condition(s)',\n",
    "    'Are you currently undergoing treatment for any dermatological condition?',\n",
    "    'If yes, specify the type of treatment'\n",
    "]\n",
    "\n",
    "# Loop through and print frequency + percentage tables\n",
    "for col in derm_columns:\n",
    "    print(f\"\\nVariable: {col}\")\n",
    "    freq_table = df[col].value_counts(dropna=False).reset_index()\n",
    "    freq_table.columns = [col, 'Frequency']\n",
    "    freq_table['Percent'] = (freq_table['Frequency'] / freq_table['Frequency'].sum()) * 100\n",
    "    print(freq_table.to_string(index=False, formatters={'Percent': '{:,.1f}%'.format}))\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "23afcff7-860c-4fb1-9941-f3d29a5e2e8d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Variable: Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?  Frequency Percent\n",
      "                                                                               Yes        572   70.2%\n",
      "                                                                                No        243   29.8%\n",
      "\n",
      "Variable: If yes, specify the symptom(s)\n",
      "                                                                                                                                                                                                                                 If yes, specify the symptom(s)  Frequency Percent\n",
      "                                                                                                                                                                                                                                                            NaN        214   26.3%\n",
      "                                                                                                                                                                                                                                                  Rash;Itching          93   11.4%\n",
      "                                                                                                                                                                                                                                                        Itching         59    7.2%\n",
      "                                                                                                                                                                                                                                                      Psoriasis         46    5.6%\n",
      "                                                                                                                                                                                                                                                         Eczema         32    3.9%\n",
      "                                                                                                                                                                                                                                                  Herpes zoster         24    2.9%\n",
      "                                                                                                                                                                                                                                                           Rash         22    2.7%\n",
      "                                                                                                                                                                                                                                                 Acne vulagaris         17    2.1%\n",
      "                                                                                                                                                                                                                                Rash;Itching ;Hyper sensitivity         14    1.7%\n",
      "                                                                                                                                                                                                                                              Hives (urticaria)         14    1.7%\n",
      "                                                                                                                                                                                                                                              Eczema ;Erythema          12    1.5%\n",
      "                                                                                                                                                                                                                                                  Discoloration         11    1.3%\n",
      "                                                                                                                                                                                                                                         Rash;Hives (urticaria)         10    1.2%\n",
      "                                                                                                                                                                                                                                                             No         10    1.2%\n",
      "                                                                                                                                                                                                                                        Itching ;Herpes zoster           7    0.9%\n",
      "                                                                                                                                                                                                                                               Itching ;Eczema           7    0.9%\n",
      "                                                                                                                                                                                                                                                       Dandruff          6    0.7%\n",
      "                                                                                                                                                                                                                                     Swelling (edema with pain)          6    0.7%\n",
      "                                                                                                                                                                                                                                   Rash;Itching ;Acne vulagaris          6    0.7%\n",
      "                                                                                                                                                                                                                   Itching ;Flare-up of pre-existing conditions          6    0.7%\n",
      "                                                                                                                                                                                                                                  Herpes zoster ;Acne vulagaris          5    0.6%\n",
      "                                                                                                                                                                                                                                                Tinea Infection          5    0.6%\n",
      "                                                                                                                                                                                                                                   Rash;Itching ;Herpes zoster           5    0.6%\n",
      "                                                                                                                                                                                                                                       Psoriasis;Acne vulagaris          5    0.6%\n",
      "                                                                                                                                                                                                                                                       Erythema          4    0.5%\n",
      "                                                                                                                                                                                                                                             Itching ;Psoriasis          4    0.5%\n",
      "                                                                                                                                                                                                                                                 Rash;Psoriasis          4    0.5%\n",
      "                                                                                                                                                                                                                                Rash;Itching ;Hives (urticaria)          4    0.5%\n",
      "                                                                                                                                                                                                                        Herpes zoster ;Dandruff ;Acne vulagaris          4    0.5%\n",
      "                                                                                                                                                                                                                                              Hyper sensitivity          4    0.5%\n",
      "                                                                                                                                                                                                                      Rash;Itching ;Swelling (edema with pain)           4    0.5%\n",
      "                                                                                                                                                                                                                                       Dandruff ;Acne vulagaris          4    0.5%\n",
      "                                                                                                                                                                                                                                              Dandruff ;Eczema           3    0.4%\n",
      "                                                                                                                                                                                                           Injection site reaction (redness, pain, or swelling)          3    0.4%\n",
      "                                                                                                                                                                                                                                         Herpes zoster ;Eczema           3    0.4%\n",
      "                                                                                                                                                                                                                                        Rash;Itching ;Dandruff           3    0.4%\n",
      "                                                                                                                                                                                                                                             Itching ;Dandruff           3    0.4%\n",
      "                                                                                                                                                                                                    Rash;Itching ;Swelling (edema with pain) ;Hives (urticaria)          3    0.4%\n",
      "                                                                                                                                                                                                                                         Rash;Hyper sensitivity          3    0.4%\n",
      "                                                                                                                                                                                                                                                 Vesicular Rash          3    0.4%\n",
      "                                                                                                                                                                                                    Rash;Itching ;Swelling (edema with pain) ;Hyper sensitivity          3    0.4%\n",
      "                                                                                                                                                                                                                                            Dandruff ;Erythema           2    0.2%\n",
      "                                                                                                                                                                                                                                       Herpes zoster ;Erythema           2    0.2%\n",
      "                                                                                                                                                                                                                                     Itching ;Hives (urticaria)          2    0.2%\n",
      "                                                                                                                                                                                                                           Itching ;Swelling (edema with pain)           2    0.2%\n",
      "                                                                                                                                                                                                              Psoriasis;Herpes zoster ;Dandruff ;Acne vulagaris          2    0.2%\n",
      "                                                                                                                                                                                                                             Psoriasis;Dandruff ;Acne vulagaris          2    0.2%\n",
      "                                                                                                                                                                                         Hives (urticaria);Injection site reaction (redness, pain, or swelling)          2    0.2%\n",
      "                                                                                                                                                                                                                                    Erythema ;Hyper sensitivity          2    0.2%\n",
      "                                                                                                                                                                                                                                            Psoriasis;Dandruff           2    0.2%\n",
      "                                                                                                                                                                                                                                       Herpes zoster ;Dandruff           2    0.2%\n",
      "                                                                                                                                                                                                                               Dandruff ;Acne vulagaris;Eczema           2    0.2%\n",
      "                                                                                                                                                                                                                                                Tinea infection          2    0.2%\n",
      "                                                                                                                                                                                                                                       Psoriasis;Herpes zoster           2    0.2%\n",
      "                                                                                                                                                                                                                                 Rash;Hives (urticaria);Eczema           2    0.2%\n",
      "                                                                                                                                                                                                                                          Rash;Itching ;Eczema           2    0.2%\n",
      "                                                                                                                                                                                                                                            Rash;Acne vulagaris          2    0.2%\n",
      "                                                                                                                                                                                                                          Swelling (edema with pain) ;Psoriasis          2    0.2%\n",
      "                                                                                                                                                                                                              Rash;Itching ;Hives (urticaria);Hyper sensitivity          2    0.2%\n",
      "                                                                                                                                                                                                                                        Itching ;Acne vulagaris          2    0.2%\n",
      "                                                                                                                                                                                                                                                   Rash;Eczema           2    0.2%\n",
      "                                                                                                                                                                                                                                         Acne vulagaris;Eczema           2    0.2%\n",
      "                                                                                                                                                                                                                          Rash;Dandruff ;Acne vulagaris;Eczema           1    0.1%\n",
      "                                                                                                                                                                                                                               Rash;Hives (urticaria);Psoriasis          1    0.1%\n",
      "                                                                                                                                                                                                                           Rash;Hives (urticaria);Discoloration          1    0.1%\n",
      "                                                                                                                                                                                                                          Rash;Hives (urticaria);Acne vulagaris          1    0.1%\n",
      "                                                                                                                                                                                                                                            Rash;Herpes zoster           1    0.1%\n",
      "                                                                                                                                                                                                                                         Rash;Psoriasis;Eczema           1    0.1%\n",
      "                                                                                                                                                                                                                     Rash;Swelling (edema with pain) ;Erythema           1    0.1%\n",
      "                                                                                                                                                                                                            Rash;Itching ;Swelling (edema with pain) ;Erythema           1    0.1%\n",
      "                                                                                                                                                                                                                                     Itching ;Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                                       Rash;Hives (urticaria);Psoriasis;Eczema           1    0.1%\n",
      "                                                                                                                                                                                                                                        Rash;Itching ;Psoriasis          1    0.1%\n",
      "                                                                                                                                                                                                                    Itching ;Psoriasis;Herpes zoster ;Erythema           1    0.1%\n",
      "                                                                                                                                                                                                                             Psoriasis;Herpes zoster ;Dandruff           1    0.1%\n",
      "                                                                                                                                                                                                                        Rash;Itching ;Eczema ;Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                                Rash;Swelling (edema with pain) ;Herpes zoster           1    0.1%\n",
      "                                                                                                                                                                                                                           Rash;Discoloration;Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                                          Rash;Vesicular Rash;Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                              Herpes zoster ;Dandruff ;Acne vulagaris;Hair loss          1    0.1%\n",
      "                                                                                                                                                                                                                                    Hives (urticaria);Dandruff           1    0.1%\n",
      "                                                                                                                                                                                                                                  Herpes zoster ;Vesicular Rash          1    0.1%\n",
      "                                                                                                                                                                                                                          Herpes zoster ;Acne vulagaris;Eczema           1    0.1%\n",
      "                                                                                                                                                                                                                     Rash;Psoriasis;Dandruff ;Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                                                        Rash;Itching ;Hair Loss          1    0.1%\n",
      "                                                                                                                                                                                                                  Hives (urticaria);Dandruff ;Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                                                        Discoloration;Dandruff           1    0.1%\n",
      "                                                                                                                                                                                                                                            Psoriasis;Hair Loss          1    0.1%\n",
      "                                                                                                                                                                                                                    Rash;Itching ;Herpes zoster ;Acne vulagaris          1    0.1%\n",
      "                                                                                                                                                                                                                       Rash;Hives (urticaria);Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                                               Rash;Hives (urticaria);Dandruff           1    0.1%\n",
      "                                                                                                                               Rash;Itching ;Hives (urticaria);Herpes zoster ;Dandruff ;Flare-up of pre-existing conditions;Eczema ;Erythema ;Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                                               Acne vulagaris;Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                                                      Dandruff ;Tinea infection          1    0.1%\n",
      "                                                                                                                                                                                                                                                        Nothing          1    0.1%\n",
      "                                                                                                                                                                                                               Itching ;Herpes zoster ;Dandruff ;Acne vulagaris          1    0.1%\n",
      "                                                                                                                                                                                                                                  Rash;Psoriasis;Herpes zoster           1    0.1%\n",
      "                                                                                                                                                                                                              Rash;Itching ;Flare-up of pre-existing conditions          1    0.1%\n",
      "                                                                                                                                                                                                                              Itching ;Herpes zoster ;Dandruff           1    0.1%\n",
      "                                                                                                                                                                                                                         Rash;Itching ;Psoriasis;Herpes zoster           1    0.1%\n",
      "                                                                                                                                                                                                                                    Rash;Itching ;Discoloration          1    0.1%\n",
      "                                                                                                                                                                                                                Rash;Psoriasis;Acne vulagaris;Hyper sensitivity          1    0.1%\n",
      "                                                                                                            Itching ;Psoriasis;Dandruff ;Acne vulagaris;Flare-up of pre-existing conditions;Injection site reaction (redness, pain, or swelling);Vesicular Rash          1    0.1%\n",
      "                                                                                                                                                                                                                               Itching ;Discoloration;Psoriasis          1    0.1%\n",
      "                                                                                                                                                                                                           Itching ;Flare-up of pre-existing conditions;Eczema           1    0.1%\n",
      "                                                                                                                                                                                                            Itching ;Psoriasis;Herpes zoster ;Dandruff ;Eczema           1    0.1%\n",
      "                                                                                                                                                                                                                                   Itching ;Psoriasis;Dandruff           1    0.1%\n",
      "Rash;Swelling (edema with pain) ;Hives (urticaria);Discoloration;Psoriasis;Herpes zoster ;Dandruff ;Acne vulagarisFlare-up of pre-existing conditions;Injection site reaction (redness, pain, or swelling);Eczema ;Erythema ;Vesicular Rash;Hyper sensitivity;           1    0.1%\n",
      "                                                                                                                                                                                               Rash;Itching ;Acne vulagaris;Flare-up of pre-existing conditions          1    0.1%\n",
      "                                                                                                                                                                                  Dandruff ;Acne vulagaris;Injection site reaction (redness, pain, or swelling)          1    0.1%\n",
      "                                                                                                                                                                                                                               Rash;Dandruff ;Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                                                            Rash;Vesicular Rash          1    0.1%\n",
      "                                                                                                                                                Hives (urticaria);Psoriasis;Herpes zoster ;Dandruff ;Acne vulagaris;Flare-up of pre-existing conditions;Eczema           1    0.1%\n",
      "                                                                                                                                                                                                                            Hives (urticaria);Eczema ;Erythema           1    0.1%\n",
      "                                                                                                                                                                                                              Itching ;Hives (urticaria);Herpes zoster ;Eczema           1    0.1%\n",
      "                                                                                                                                                                                                                      Itching ;Herpes zoster ;Eczema ;Erythema           1    0.1%\n",
      "                                                                                                                                                                                                                                                        Eczema           1    0.1%\n",
      "                                                                                                                                                                                                                                  Rash;Itching ;Tinea infection          1    0.1%\n",
      "                                                                                                                                                                                                 Psoriasis;Injection site reaction (redness, pain, or swelling)          1    0.1%\n",
      "                                                                                                                                                                                                                                           Rash;Tinea Infection          1    0.1%\n",
      "                                                                                                                                                                                                                              Hives (urticaria);Tinea infection          1    0.1%\n",
      "                                                                                                                                                                                                                              Hives (urticaria);Tanea infection          1    0.1%\n",
      "                                                                                                                                                                                                                                  Rash;Itching ;Tanea infection          1    0.1%\n",
      "                                                                                                                                                                                                                               Hives (urticaria);Herpes zoster           1    0.1%\n",
      "                                                                                                                                                                                                                                 Acne vulagaris;Tanea infection          1    0.1%\n",
      "                                                                                                                                                                                                                                            Dandruff ;Hair Loss          1    0.1%\n",
      "                                                                                                                                                                                                                                   Itching ;Dandruff ;Hair loss          1    0.1%\n",
      "                                                                                                                                                                                                                                            Dandruff ;Hair loss          1    0.1%\n",
      "                                                                                                                                                                                                                               Rash;Swelling (edema with pain)           1    0.1%\n",
      "                                                                                                                                                                                                                                               Eczema ;Erythema          1    0.1%\n",
      "                                                                                                                                                                                                                                     Itching ;Eczema ;Erythema           1    0.1%\n",
      "                                                                                                                                                                                                          Psoriasis;Flare-up of pre-existing conditions;Eczema           1    0.1%\n",
      "                                                                                                                                                                                                                            Eczema ;Erythema ;Hyper sensitivity          1    0.1%\n",
      "                                                                                                                                                                                                                                       Erythema ;Vesicular Rash          1    0.1%\n",
      "                                                                                                                                                                                                                                                 Rash;Dandruff           1    0.1%\n",
      "                                                                                                                                                                                           Itching ;Dandruff ;Acne vulagarisFlare-up of pre-existing conditions          1    0.1%\n",
      "                                                                                                                                                                                                                  Dandruff ;Flare-up of pre-existing conditions          1    0.1%\n",
      "                                                                                                                                                                                                                                    Dandruff ;Eczema ;Erythema           1    0.1%\n",
      "                                                                                                                                                                               Dandruff ;Injection site reaction (redness, pain, or swelling);Eczema ;Erythema           1    0.1%\n",
      "                                                                                                                                                                                                                                             Itching ;Erythema           1    0.1%\n",
      "\n",
      "Variable: When did these symptoms appear?\n",
      "       When did these symptoms appear?  Frequency Percent\n",
      "                     Later than a week        382   46.9%\n",
      "                                   NaN        223   27.4%\n",
      "                              4-7 days         77    9.4%\n",
      "                              1-3 days         55    6.7%\n",
      "                       Within 24 hours         27    3.3%\n",
      "                          1 year later         22    2.7%\n",
      "                                    No          8    1.0%\n",
      "                               3 month          4    0.5%\n",
      "                          after 2 year          4    0.5%\n",
      "                          After 3 year          2    0.2%\n",
      "                                 Never          2    0.2%\n",
      "                          After 2 year          2    0.2%\n",
      "                           No symptom           1    0.1%\n",
      "After 7 /8 month,the symptoms appeared          1    0.1%\n",
      "                            No symtoms          1    0.1%\n",
      "                           Few months           1    0.1%\n",
      "                               6 month          1    0.1%\n",
      "                              Nothing           1    0.1%\n",
      "                  I would not observe           1    0.1%\n",
      "\n",
      "Variable: How severe were the symptoms?\n",
      "How severe were the symptoms?  Frequency Percent\n",
      "                     Moderate        402   49.3%\n",
      "                          NaN        219   26.9%\n",
      "                         Mild        125   15.3%\n",
      "                       Severe         69    8.5%\n",
      "\n",
      "Variable: How long did the symptoms last?\n",
      "How long did the symptoms last?  Frequency Percent\n",
      "               More than a week        421   51.7%\n",
      "                            NaN        210   25.8%\n",
      "                       1-3 days        114   14.0%\n",
      "                Less than a day         70    8.6%\n",
      "\n",
      "Variable: Did you seek medical attention for these symptoms?\n",
      "Did you seek medical attention for these symptoms?  Frequency Percent\n",
      "                                               Yes        445   54.6%\n",
      "                                               NaN        194   23.8%\n",
      "                                                No        176   21.6%\n",
      "\n",
      "Variable: If yes, what type of treatment did you receive?\n",
      "If yes, what type of treatment did you receive?  Frequency Percent\n",
      "                        Prescription medication        441   54.1%\n",
      "                                            NaN        286   35.1%\n",
      "                    Over-the-counter medication         44    5.4%\n",
      "                               Other (Specify))         44    5.4%\n",
      "\n",
      "Variable: Did these symptoms resolve completely?\n",
      "Did these symptoms resolve completely?  Frequency Percent\n",
      "                                    No        467   57.3%\n",
      "                                   NaN        193   23.7%\n",
      "                                   Yes        155   19.0%\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Clean column names (if not already done)\n",
    "df.columns = df.columns.str.strip()\n",
    "\n",
    "# Skin reaction-related variables\n",
    "skin_reaction_columns = [\n",
    "    'Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?',\n",
    "    'If yes, specify the symptom(s)',\n",
    "    'When did these symptoms appear?',\n",
    "    'How severe were the symptoms?',\n",
    "    'How long did the symptoms last?',\n",
    "    'Did you seek medical attention for these symptoms?',\n",
    "    'If yes, what type of treatment did you receive?',\n",
    "    'Did these symptoms resolve completely?'\n",
    "]\n",
    "\n",
    "# Loop through and print frequency + percentage\n",
    "for col in skin_reaction_columns:\n",
    "    print(f\"\\nVariable: {col}\")\n",
    "    freq_table = df[col].value_counts(dropna=False).reset_index()\n",
    "    freq_table.columns = [col, 'Frequency']\n",
    "    freq_table['Percent'] = (freq_table['Frequency'] / freq_table['Frequency'].sum()) * 100\n",
    "    print(freq_table.to_string(index=False, formatters={'Percent': '{:,.1f}%'.format}))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "884319b4-49c4-4cc4-ae26-10a8f600e1c0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x800 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Assuming the CSV is already loaded into a DataFrame called 'df'\n",
    "# If not, uncomment and adjust the line below to load your CSV\n",
    "# df = pd.read_csv('covid.csv')\n",
    "\n",
    "# Sample data based on the image (replace with actual data from your CSV)\n",
    "side_effect_data = {'Category': ['Yes', 'No'], 'Percentage': [70.2,29.8]}\n",
    "\n",
    "# Create a DataFrame\n",
    "df = pd.DataFrame(side_effect_data)\n",
    "\n",
    "# Create the pie chart\n",
    "fig, ax = plt.subplots(figsize=(8, 8))\n",
    "ax.pie(df['Percentage'], labels=df['Category'], autopct='%1.1f%%', colors=['#d4a373', '#98d7a5'], startangle=90)\n",
    "ax.axis('equal')  # Equal aspect ratio ensures that pie is drawn as a circle\n",
    "ax.set_title('Skin-Related Side Effect After Vaccination')\n",
    "\n",
    "# Display the plot\n",
    "plt.savefig(\"pier.png\", dpi=300, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "74c95a4f-5a8b-4f4d-95e3-23ab127a0978",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Variable: Did these dermatological side effects affect your daily activities?\n",
      "Did these dermatological side effects affect your daily activities?  Frequency Percent\n",
      "                                                                Yes        509   62.5%\n",
      "                                                                 No        240   29.4%\n",
      "                                                                NaN         66    8.1%\n",
      "\n",
      "Variable: If yes, specify how they impacted you\n",
      "                                              If yes, specify how they impacted you  Frequency Percent\n",
      "                                                                                NaN        264   32.4%\n",
      "                                                         Work or school performance        134   16.4%\n",
      "                                     Work or school performance;Social interactions        129   15.8%\n",
      "                                                                Social interactions         88   10.8%\n",
      "                                                               Emotional well-being         62    7.6%\n",
      "                Work or school performance;Social interactions;Emotional well-being         53    6.5%\n",
      "                                                                    Other (Specify)         40    4.9%\n",
      "                                           Social interactions;Emotional well-being         23    2.8%\n",
      "                                    Work or school performance;Emotional well-being         13    1.6%\n",
      "                                                Social interactions;Other (Specify)          4    0.5%\n",
      "                           Social interactions;Emotional well-being;Other (Specify)          1    0.1%\n",
      "                                               Emotional well-being;Other (Specify)          1    0.1%\n",
      "                                         Work or school performance;Other (Specify)          1    0.1%\n",
      "                     Work or school performance;Social interactions;Other (Specify)          1    0.1%\n",
      "Work or school performance;Social interactions;Emotional well-being;Other (Specify)          1    0.1%\n",
      "\n",
      "Variable: Do you believe the COVID-19 vaccine caused or worsened your skin symptoms?\n",
      "Do you believe the COVID-19 vaccine caused or worsened your skin symptoms?  Frequency Percent\n",
      "                                                                       Yes        568   69.7%\n",
      "                                                                        No        103   12.6%\n",
      "                                                                  Not Sure         99   12.1%\n",
      "                                                                       NaN         45    5.5%\n",
      "\n",
      "Variable: Do you have concerns about receiving future doses due to these side effects?\n",
      "Do you have concerns about receiving future doses due to these side effects?  Frequency Percent\n",
      "                                                                         Yes        629   77.2%\n",
      "                                                                          No        139   17.1%\n",
      "                                                                         NaN         47    5.8%\n",
      "\n",
      "Variable: Would you recommend COVID-19 vaccination to others despite these side effects?\n",
      "Would you recommend COVID-19 vaccination to others despite these side effects?  Frequency Percent\n",
      "                                                                            No        395   48.5%\n",
      "                                                                           Yes        236   29.0%\n",
      "                                                           Conditional-Specify        135   16.6%\n",
      "                                                                           NaN         49    6.0%\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Clean column names if not done already\n",
    "df.columns = df.columns.str.strip()\n",
    "\n",
    "# Final section: beliefs & impact of dermatological side effects\n",
    "impact_belief_columns = [\n",
    "    'Did these dermatological side effects affect your daily activities?',\n",
    "    'If yes, specify how they impacted you',\n",
    "    'Do you believe the COVID-19 vaccine caused or worsened your skin symptoms?',\n",
    "    'Do you have concerns about receiving future doses due to these side effects?',\n",
    "    'Would you recommend COVID-19 vaccination to others despite these side effects?'\n",
    "]\n",
    "\n",
    "# Loop through and show frequency & percentage\n",
    "for col in impact_belief_columns:\n",
    "    print(f\"\\nVariable: {col}\")\n",
    "    freq_table = df[col].value_counts(dropna=False).reset_index()\n",
    "    freq_table.columns = [col, 'Frequency']\n",
    "    freq_table['Percent'] = (freq_table['Frequency'] / freq_table['Frequency'].sum()) * 100\n",
    "    print(freq_table.to_string(index=False, formatters={'Percent': '{:,.1f}%'.format}))\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "993b4e72-f23e-4450-a7a9-fe5143403ce1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "\n",
    "# df = pd.read_csv('covid.csv')\n",
    "\n",
    "\n",
    "vaccine_data = {\n",
    "    'Vaccine Name': [\"Don't Know the name\", \"Sinovac\", \"Sinopharm\", \"Moderna\", \"Pfizer\", \"AstraZeneca\"],\n",
    "    'Percentage of Side Effects': [92.8, 53.8, 74.3, 72.1, 56.1, 52.7]\n",
    "}\n",
    "\n",
    "\n",
    "df = pd.DataFrame(vaccine_data)\n",
    "\n",
    "# Create the bar plot\n",
    "plt.figure(figsize=(10, 6))\n",
    "plt.bar(df['Vaccine Name'], df['Percentage of Side Effects'], color=['#2ecc71', '#27ae60', '#3498db', '#9b59b6', '#e74c3c', '#f1c40f'])\n",
    "plt.title('Bar Plot')\n",
    "plt.xlabel('Vaccine Name')\n",
    "plt.ylabel('Percentage of Side Effects')\n",
    "plt.xticks(rotation=45, ha='right')\n",
    "plt.tight_layout()\n",
    "\n",
    "# Display the plot\n",
    "plt.savefig(\"brr.png\", dpi=300, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "66ec8c71-d341-4471-ba75-16f5523c6b7a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Variable: Age of the participants\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?           No  \\\n",
      "Age of the participants                                                                           \n",
      "20-29 years                                                                         148 (40.1%)   \n",
      "30-39 years                                                                          40 (24.2%)   \n",
      "40-49 years                                                                          27 (26.0%)   \n",
      "50-59 years                                                                           7 (18.4%)   \n",
      "<20 years                                                                            20 (22.0%)   \n",
      "Greater than 60                                                                        1 (5.6%)   \n",
      "\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?          Yes  \n",
      "Age of the participants                                                                          \n",
      "20-29 years                                                                         221 (59.9%)  \n",
      "30-39 years                                                                         125 (75.8%)  \n",
      "40-49 years                                                                          77 (74.0%)  \n",
      "50-59 years                                                                          31 (81.6%)  \n",
      "<20 years                                                                            71 (78.0%)  \n",
      "Greater than 60                                                                      17 (94.4%)  \n",
      "P-value: 0.0000\n",
      "\n",
      "Variable: Gender of the participants\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?           No  \\\n",
      "Gender of the participants                                                                        \n",
      "Female                                                                              135 (33.5%)   \n",
      "Male                                                                                108 (28.3%)   \n",
      "female                                                                                 0 (0.0%)   \n",
      "\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?          Yes  \n",
      "Gender of the participants                                                                       \n",
      "Female                                                                              268 (66.5%)  \n",
      "Male                                                                                273 (71.7%)  \n",
      "female                                                                               1 (100.0%)  \n",
      "P-value: 0.2368\n",
      "\n",
      "Variable: Religion of the participants\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?           No  \\\n",
      "Religion of the participants                                                                      \n",
      "Hindu                                                                                29 (26.1%)   \n",
      "Muslim                                                                              214 (32.4%)   \n",
      "Other                                                                                  0 (0.0%)   \n",
      "\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?          Yes  \n",
      "Religion of the participants                                                                     \n",
      "Hindu                                                                                82 (73.9%)  \n",
      "Muslim                                                                              447 (67.6%)  \n",
      "Other                                                                               13 (100.0%)  \n",
      "P-value: 0.0217\n",
      "\n",
      "Variable: Location of the participants\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?           No  \\\n",
      "Location of the participants                                                                      \n",
      "Other                                                                                 3 (23.1%)   \n",
      "Rural                                                                               141 (38.2%)   \n",
      "Urban                                                                                99 (24.6%)   \n",
      "\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?          Yes  \n",
      "Location of the participants                                                                     \n",
      "Other                                                                                10 (76.9%)  \n",
      "Rural                                                                               228 (61.8%)  \n",
      "Urban                                                                               304 (75.4%)  \n",
      "P-value: 0.0002\n",
      "\n",
      "Variable: Education of the participants\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?           No  \\\n",
      "Education of the participants                                                                     \n",
      "Higher Secondary                                                                     44 (28.4%)   \n",
      "No education                                                                          1 (33.3%)   \n",
      "Primary                                                                              32 (43.2%)   \n",
      "Secondary                                                                            22 (23.2%)   \n",
      "University or above                                                                 144 (31.4%)   \n",
      "\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?          Yes  \n",
      "Education of the participants                                                                    \n",
      "Higher Secondary                                                                    111 (71.6%)  \n",
      "No education                                                                          2 (66.7%)  \n",
      "Primary                                                                              42 (56.8%)  \n",
      "Secondary                                                                            73 (76.8%)  \n",
      "University or above                                                                 314 (68.6%)  \n",
      "P-value: 0.0759\n",
      "\n",
      "Variable: Occupation of the participants\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?           No  \\\n",
      "Occupation of the participants                                                                    \n",
      "Employed                                                                             46 (18.9%)   \n",
      "House Wife                                                                           20 (35.7%)   \n",
      "Student                                                                             165 (41.6%)   \n",
      "Unemployed                                                                           12 (13.6%)   \n",
      "\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?          Yes  \n",
      "Occupation of the participants                                                                   \n",
      "Employed                                                                            198 (81.1%)  \n",
      "House Wife                                                                           36 (64.3%)  \n",
      "Student                                                                             232 (58.4%)  \n",
      "Unemployed                                                                           76 (86.4%)  \n",
      "P-value: 0.0000\n",
      "\n",
      "Variable: Health Status of the participants\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?           No  \\\n",
      "Health Status of the participants                                                                 \n",
      "Excellent                                                                            10 (31.2%)   \n",
      "Good                                                                                216 (32.9%)   \n",
      "Poor                                                                                 17 (17.7%)   \n",
      "\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?          Yes  \n",
      "Health Status of the participants                                                                \n",
      "Excellent                                                                            22 (68.8%)  \n",
      "Good                                                                                441 (67.1%)  \n",
      "Poor                                                                                 79 (82.3%)  \n",
      "P-value: 0.0110\n",
      "\n",
      "Variable: Which vaccine did you receive?\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?          No  \\\n",
      "Which vaccine did you receive?                                                                   \n",
      "AstraZeneca                                                                         53 (47.3%)   \n",
      "Don't Know the name                                                                   6 (4.3%)   \n",
      "Moderna                                                                             46 (27.9%)   \n",
      "Pfizer                                                                              97 (43.9%)   \n",
      "Sinopharm                                                                           35 (25.7%)   \n",
      "Sinovac                                                                              6 (46.2%)   \n",
      "\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?          Yes  \n",
      "Which vaccine did you receive?                                                                   \n",
      "AstraZeneca                                                                          59 (52.7%)  \n",
      "Don't Know the name                                                                 132 (95.7%)  \n",
      "Moderna                                                                             119 (72.1%)  \n",
      "Pfizer                                                                              124 (56.1%)  \n",
      "Sinopharm                                                                           101 (74.3%)  \n",
      "Sinovac                                                                               7 (53.8%)  \n",
      "P-value: 0.0000\n",
      "\n",
      "Variable: How many doses have you received?\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?           No  \\\n",
      "How many doses have you received?                                                                 \n",
      "1                                                                                    23 (31.1%)   \n",
      "2                                                                                   166 (45.7%)   \n",
      "3                                                                                    49 (14.8%)   \n",
      "More                                                                                  3 (23.1%)   \n",
      "\n",
      "Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?          Yes  \n",
      "How many doses have you received?                                                                \n",
      "1                                                                                    51 (68.9%)  \n",
      "2                                                                                   197 (54.3%)  \n",
      "3                                                                                   283 (85.2%)  \n",
      "More                                                                                 10 (76.9%)  \n",
      "P-value: 0.0000\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import scipy.stats as stats\n",
    "\n",
    "# Clean column names (if not already done)\n",
    "df.columns = df.columns.str.strip()\n",
    "\n",
    "# Target variable (must match exactly your column name)\n",
    "target = 'Did you experience any skin-related symptoms after receiving the COVID-19 vaccine?'  # Yes/No\n",
    "\n",
    "# List of independent categorical variables\n",
    "independent_vars = [\n",
    "    'Age of the participants',\n",
    "    'Gender of the participants',\n",
    "    'Religion of the participants',\n",
    "    'Location of the participants',\n",
    "    'Education of the participants',\n",
    "    'Occupation of the participants',\n",
    "    'Health Status of the participants',\n",
    "    'Which vaccine did you receive?',\n",
    "    'How many doses have you received?'\n",
    "]\n",
    "\n",
    "# Loop through each variable and do crosstab + chi-square test\n",
    "for var in independent_vars:\n",
    "    print(f\"\\nVariable: {var}\")\n",
    "    \n",
    "    # Crosstab\n",
    "    ct = pd.crosstab(df[var], df[target], margins=False)\n",
    "\n",
    "    # Percent row-wise (optional)\n",
    "    percent_ct = ct.div(ct.sum(axis=1), axis=0) * 100\n",
    "    \n",
    "    # Combine frequency and percentage nicely\n",
    "    formatted_table = ct.astype(str) + ' (' + percent_ct.round(1).astype(str) + '%)'\n",
    "    print(formatted_table)\n",
    "\n",
    "    # Chi-square test\n",
    "    chi2, p, dof, expected = stats.chi2_contingency(ct)\n",
    "    print(f\"P-value: {p:.4f}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "cf351674-394d-4a25-888d-751a5368d6ab",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAoAAAAKSCAYAAABC02qzAAAAOnRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjEwLjUsIGh0dHBzOi8vbWF0cGxvdGxpYi5vcmcvWftoOwAAAAlwSFlzAAAPYQAAD2EBqD+naQAAVPxJREFUeJzt3Qec3VWd///PvXd67zNpkx5SCKRQQycIWBdsC+uKuljWtupfV9cV2yIouroqim1Xwbb7k64iJUCAJEAqCYT0MpPpvd65c+v3/zgnmWGSTKbPnG95PR+Py83cubl87p2b3Hc+p/ksy7IEAAAAnuE3XQAAAACmFgEQAADAYwiAAAAAHkMABAAA8BgCIAAAgMcQAAEAADyGAAgAAOAxBEAAAACPIQACAAB4DAEQ8LA5c+bIBz/4wQl7PJ/PJ9/4xjfE7u69915d67Zt24a8n3ou6n6mPPfcc/r/r66Hc+WVV+qLaQcPHpRrr71WcnNzde2PPPKIvn3r1q2yZs0ayczM1Lfv3LnTdKmApyWZLgCAs/ztb3+TLVu2OCLoYep94AMfkKNHj8odd9wheXl5ct5550k0GpX3vOc9kpaWJv/1X/8lGRkZMnv27An9/9bW1sovf/lLueGGG2TFihUT+tiAGxEAAQ/bv3+/+P3+UQfAn/70p4MGwFAoJElJ7vlr5bbbbpN/+7d/M/b/v/zyy/VrmpKSIk6gan3ppZfkK1/5inzqU5/qv33fvn1SWVkpv/rVr+TDH/7wpPy/VQD85je/qbvaBEBgeO75mxqwmUQiIZFIRHc97Co1NXVCH8/Oz3UsVJg1GWhVOHfSa9rU1KSvVedvoMbGxkFvB2AOcwCBYfTNA1NdjPe+972Sk5MjhYWF8pnPfEZ6e3v776fuo7oef/jDH2TZsmU6XD3xxBP6ezU1NfJP//RPUlpaqm9X3//1r389pnoef/xxueyyy/RcquzsbHnrW98qr7/+ev/3n332WR0cvva1r530+/74xz/qGn/2s5+dcQ6gGqpTXZSFCxfq4KGe56WXXirr1q3T31f3Vd2/vufbdxn4GgzsDPa9docOHdK/VwUANTfsQx/6kPT09JzWPfqXf/kXKSoq0s/rHe94h37dxjKv8P/+7/9k9erV+nHUz2v58uXyox/9aMjf09bWJhdccIHMnDlTd0YH1j9Q389ZzW07++yz+3+efT/riazzTHMA1VDn/PnzJT09Xde8YcOGQR8/HA7L17/+dVmwYIGuc9asWfLFL35R3z5a6v3/7ne/WwoKCvR7Qw3t/vnPf+7/vnqt+oZ1//Vf/1XX3ff+uuKKK/TtahhY3T5wruJwj9unvb1dPve5z+nHVM9F/ZxuueUWaW5u1q/P+eefr++n3lt970s11xPA4OgAAiOkwp/68Pn2t78tL7/8svz4xz/WoeG3v/3tSeHrT3/6kw4IKsio+zc0NMhFF13UHxyKi4t1iLv11luls7NTPvvZz464ht/97nd6jtV1110nd911lw5RKtCpkPbKK6/o/9/VV18tn/jEJ3Sdaj7UqlWrpK6uTj796U/LNddcI//8z/98xsdXH+Lq96lhOhUsVH1qocSOHTvkTW96k3zsYx/TQ20qEKpaRvPazZ07Vz+2eqz//u//lpKSEv0c+qigoF6797///fr1ev7553W4HS1V28033yxr167tf/y9e/fKpk2bdGgfjAoR6vm1trbq/68KV0PZuHGjPPTQQ/p1VuFNvRfe9a53ybFjx3Ronqw6lf/5n//RPwe1oEK9d44cOaLDsgpQKuAN7ECr21WtH/3oR2XJkiXy2muv6Tl4Bw4c6F+cMRLqHxiXXHKJzJgxQw+Jq398qJ+Ven89+OCDcuONN8o73/lOHfBVSFPP6y1veYtkZWXpf/So33fnnXfqgK+CmrptpI+rdHd363/0qNdH/UNKvafVz0wFxerqav3c/uM//kP/o0c9V3VfRb1GAM7AAjCkr3/965b6o/KOd7zjpNs/8YlP6Nt37dqlv1a/9vv91uuvv37S/W699VZr2rRpVnNz80m333TTTVZubq7V09Mzojq6urqsvLw86yMf+chJt9fX1+vHGXh7MBi0FixYYC1btszq7e213vrWt1o5OTlWZWXlSb939uzZ1gc+8IH+r88991x936F88pOf1M91MOp29Xqd+tr90z/900n3u/HGG63CwsL+r7dv367v99nPfvak+33wgx887TGH85nPfEY/11gsdsb7/OY3v9GPu3XrVquurk6/TvPmzbMqKipOul9f/ac+x5SUFOvQoUP9t6n3gLr97rvvntA6169frx9XXSuRSMQqKSmxVqxYYYXD4f77/fKXv9T3u+KKK/pv+93vfqffjxs2bDjpMX/+85/r+27atGnEta5du9Zavny5fi/1SSQS1po1a6yFCxf233b06FH92N/73vcGfR7333//mB73a1/7mv79Dz300Gm1qfsr6mep7qN+tgCGxxAwMEKf/OQnT/paddT6FkX0UUNdS5cu7f9a5QXVyXj729+uf626Fn0X1cXr6OjQHbGRdozUMJjqrgx8nEAgIBdeeKGsX7++/75qlaUa/lIdE7WQ4LHHHtOdn/Ly8iH/H6qDo7oyaiuPiXRq11F1aFpaWnSHUekbPlUdtcFe49FQzyEYDPYPWw9FdY/Uz0wNfb/wwgsjXpmqOqkDu4TnnHOOHsJV3bjJqLOP6saq+XTq9Ry4MER1T9XQ+kD333+/7owtXrz4pPeL6hArA98vQ1FdUdXZVl3crq6u/sdRPz/1HlbvFTVUP1qjeVz1Z+jcc8/t7wgOZHKbHsDJGAIGRkjNixtIBQA1166ioqL/NjXMeeqkeBXa1JwtdRlM3wT54fSFsr4P8FOpADKQGlr7+Mc/rufsqQ9UNXQ2HDWM9nd/93eyaNEiPb/t+uuv10OyKuCMx6nBMz8/X1+rIXRVt1ohql7LU18/NXdttFSIVMOIb37zm/XQotqTToUM9VxOpZ6bWuShgnJZWdmYn0/fc1LPZzLq7KNep8Hei8nJyTJv3rzT3i/qeakpB+N536n5m+ofL1/96lf15UyPpZ7DaIzmcQ8fPqyH2AFMHAIgMEaDdR7UpPyB1Dws5R//8R/13L3BjDRc9T2Wmns3WFg5dbWqmujft3hAfYCq+YKqMzgU1S1U93300Uflqaee0nP1VOfw5z//+bi271BdysEcH1GdWGpuodpk+Mknn9RzLdXlN7/5jV4wcN999510XzVvTc3hVAsv1PzEqXw+o6lzLNT7RS0q+cEPfjDo9wfOFxzucZQvfOEL+h8SgxlLUJ+sxwUwMgRAYIRUR2Vgh0p1MNSHmFp4cSaq+6IWCcTjcT1sOB59Q44qOIzksdTqT9UB+s///E/50pe+pCfZq8UKw1GLCdRKSnVRk+9VKFSLQ/oC4GQMuamhV/Vaqg2EB3a31Gs8Fmp4VA27q4t6XNVt+8UvfqE7TQNDhRpiVl+rxQNqCHWq9/wbaZ19+oao1XtxYCdYDWGr104Nkw58v+zatUsvMhnPz6yvs6i6jON9D4/1cdVz2b1795D3YSgYGB3mAAIj1Lf9SZ+7775bX6shvKE6RWroSs1hGuwDrG/ftJFQXRI1XKpWU6oP/KEea/PmzTr4qVWin//85/W2HD/5yU/0CtehqPlXA6lVnCqIDNw2RK3UVNTQ9kTp6wDdc889g77Go3Hqc1BDy31d1sG2P1FhS3WhvvzlL5+0Rc5kG22ditoiRf2jQnVk1R6TfdR8z1N/Hmo4Wc2hU5svn0ptuaPmH46E+geH2rZFBVO1mnw87+GxPq76M6TC7MMPP3zGrutkvC8BN6MDCIyQ6rCobTXUHC112sHvf/97+Yd/+IeTui6D+c53vqMn3KuFGh/5yEf0IhE1AV4t/nj66af1r0dChT8VUNS8NbUNxk033aTDgNp6RC3yUHP+VMhTexOq4WbVSVPHcSlqb7+//OUvuquntgLp+7A8lapNfSirvelUJ1AtOnjggQdOOtVBfU9RW3qo4KZCrqplPNRjqg/5H/7whzoY9W0Do7YrGW13R3Uq1WuqOmRqrzg1b04FSXU6hFoUMZjvfe97ekGOWuijOrZqyH6yjaVO1S371re+pbeBUb/v7//+7/X7Ug0dnzoHUL1P1BxDtWBEvf/U+0N1otW+e+p2NfSsAuVI//GjthpSQ8rqPaz+X2p7I/XnQC2kUeFsLEb6uOofMOp9qPYRVHNZ1ftFvXZqGxgVhtWfQdUlVAtr1NfqZ6je4+rP3KnzSgGcMIKVwoCn9W0FsmfPHuvd7363lZ2dbeXn51uf+tSnrFAo1H8/dR+1RcpgGhoa9PdmzZplJScnW2VlZXoLDLV9x2ipLTWuu+46vfVLWlqaNX/+fL1dyrZt2/T3P/e5z1mBQMDavHnzSb9PfT8pKcn6+Mc/fsZtYL71rW9ZF1xwgd5uJj093Vq8eLF1xx136O1H+qhtSz796U9bxcXFls/nO2mblDNtA9PU1DToNixq25CBW9eo16igoMDKysqybrjhBmv//v36ft/5zndG/Po88MAD1rXXXqu3S1HbtZSXl1sf+9jH9HYvp/7/1dYhfeLxuHXzzTfr1+iRRx45qf6BzvRzPvW1nIg6T90Gps8999xjzZ0710pNTbXOO+8864UXXtBbwAzcBkZRP7e77rpLb3Oj7qvet6tXr7a++c1vWh0dHdZoHD582Lrlllv0e1e9h2fMmGG97W1v089jrNvAjPRxlZaWFv1nTn1fvV4zZ87Ur/fA7ZUeffRRa+nSpfpnyJYwwNB86j99YRDA6dT8N9VBU0NSanNnTB21SGLlypW62/q+973PdDkA4BrMAQRgC2pe2qnUkLCaG6cWogAAJg5zAAEbUN1FNT9rqNWiak6em333u9+V7du3y1VXXaW3tOnbGkUd7aW2LFGvz3ALDtSiFXUxySl1Kmre42DBe6DR7I8IwDkIgIANqPNR+zb5HYw6raJvTz+3Uue2qlMxbr/9dr39jNpsWQ2/f+UrX9Hfr6qqGnZCv9r6Rv0ek5xSp6LOHB5uz0FmCQHuxBxAwAY2bdo0ZCdGnTLRt/rWq9Tq5o0bNw55H7WK9NTVsFPNKXUqe/bskdra2iHvM5F7/wGwDwIgAACAx7AIBAAAwGMIgAAAAB5DAAQAAPAYAiAAAIDHEAABAAA8hgAIAADgMQRAAAAAjyEAAgAAeAwBEAAAwGMIgAAAAB5DAAQAAPAYAiAAAIDHEAABAAA8hgAIAADgMQRAAAAAjyEAAgAAeAwBEAAAwGMIgAAAAB5DAAQAAPAYAiAAAIDHEAABAAA8hgAIAADgMQRAAAAAjyEAAgAAeAwBEAAAwGMIgAAAAB5DAAQAAPAYAiAAAIDHJJkuAACGY1kJifcGJR4JSSIWkUQsLIlo+MR1ROIDvz5xW999rHhM/34RSz2QWNbxa/X1K0sXi4hPfOp/4jt+7ff5JeALSJK6+JNOXAeO36a/TtJfq1+n+pMlNZAqafqSon+d7OevVQD2x99UAIxJxKMSC3VKLNSlL1H9676vB1yHgyI6xE2slnDZhD+mCop9YbAvGKYH0iQzOUOykjIkMznzxHW6vi8AmEAABDBpVOctGmyXSGeThLuaJaIunU0SDbZKNNQliUhI3CZuxSUYC+nLcAYGwyx9nSk5KVmSl5KjrwmIACYLARDAuKgh1VhPh4S7miTSeSLk6UuTRLpaxUrETJdoW6F4r740S+tp31MD0tnJmZKbki25KTmSN+A6MylDfD49cA0AY0IABDBiav5db1ut9LbWSKi1RnrbaiTc0ShWPGq6NNexxJLOaLe+VAXrTvqempeYn5orhan5UpiWL0X6Ok+S/cnG6gXgLARAAINSCy76g15f2OtsmpS5eBidmBWXpt5WfZGON27PSc6SorR8KUwtkKK0PB0Q1RAzAJyKAAhAr5jtaaqUUEtVf+iLdqthSbVaFk7R1zE80lXVf1tGUrqUphVJaXqRlGYUSXFaAXMLAYjP0nsiAPBad6+n8agEG49IT+MRHfqsRFy8ZuN5q8RrAj6/FKUVSGl6sZSlF0lZerGkJ6WZLgvAFKMDCHiA2kalp+HI8cDXcER622tP7IUHr4lbCWkINevLqwOGjlUQnJFZpi+ZSemGqwQw2QiAgAvFersk2HBYgg3HO3zh9gaGczHs0PGBzqP66/yUXJmRWSozMspkekappARYXAK4DUPAgAuoP8ZqGLerZo901+yVUEs1gW8EvDgEPFp+8UlJepHMyCjV3UE1l1CdlgLA2QiAgEPFo2EJ1h+Uruo90l27T5+YgdEhAI5eij9ZZmaWSXnWDCnPnM78QcChGAIGHCTS1aK7fF01e/VcPjZZxlSLJKJ6lbG6qM2qS9ILZXbWDJmTNVPvTQjAGegAAjam/niGmiul89hrOvRFOhtNl+QqdAAnljrCTofB7Jl66xlOKwHsiwAI2JDah6+j4hXprNwl0WCb6XJciwA4edT+g/Oyy2VBzmw9bxCAvRAAAZtQp2yo0NdRsZNO3xQhAE4Ntc3M/JzZOgwWpOaZLgcAARAwKxpsl47KnTr09baqlbuYSgTAqVeQmivzs+foMJiTkmW6HMCzCIDAFIv1BqXz2C7d7etprGC7FoMIgGaVpBXKwpw5siB3jqQFUk2XA3gKARCYAuqPWbDugLQefFm6a/Z48tg1OyIA2ud4ujlZs2Rx3ny93yCLR4DJxzYwwCSKhbqk7fBWaTu0WaLdLabLAWx7PN3hrkp9yU7OlMW58+Ws3HmSmZxhujTAtegAApPR7as/KG0HX5au6tfp9tkYHUD7UnsMzsqcpruCamsZTh8BJhYdQGACz99V3b72Q1sk0tVsuhzA0Syx5FiwVl/SA2k6CC7LW0hXEJggdACB8Xb7Gg4d7/ZV7abb5zB0AJ13LvHc7FmyvGAxewsC40QHEBiDRDwmHRU7pGXP8xLuaDBdDuAJCbHkcNcxfVEriM/OXyTzcmbrRSQARocOIDAK8UhIWg++JK37Nkos1Gm6HIwTHUB3nDiyNG+BLM1bKOlJaabLARyDAAiMcMPmln0v6NW8iWjYdDmYIARA91BdwPk5c2RFwRLJT801XQ5gewRAYAi9bXXSvOc56azcyfw+FyIAutOcrJmyquhsKU4rMF0KYFvMAQQG0V13UFr2PCfddftNlwJglCq6q/VlZmaZrCxcJtMzSk2XBNgOARA4QTXDO4+9Ks2vPyu9rTWmywEwTtXBen0pSy+WlYVLpTxrhumSANtgCBgQkc6q16Xp1Selt63WdCmYQgwBe0thar7uCM7LnsVxc/A8AiA8rbt2vzTuekJCLVWmS4EBBEBvyk/JlfOKz9FBEPAqAiA8Kdh4RBp3PiE9jUdMlwKDCIDephaJnF98rj5yDvAaAiA8JdR8TBp2PSHBugOmS4ENEAChTM8o0UFQzRUEvIIACE9Qc/sadz0pXdWvmy4FNkIAxEDlmdPlguJzpTAt33QpwKRjFTBcLdzZpINfZ+Uufbw8AJzJsWCtvizImS3nFZ0juSnZpksCJg0BEK4Uj/RK02vrpHX/RjZwBjAqhzor5UhnlSzLXyiri5ZLaiDFdEnAhGMIGK5iWQlpP7RVGnY9LvHebtPlwOYYAsZw0gKpcn7RObI4b774fX7T5QAThgAI1wg2HpX6bY+wiTNGjACIkSpIzZOLS1bp00UANyAAwvGiwXap3/FXfV4vMBoEQIzW7KwZOggyPxBOxxxAOFYiFtXHtjXveU6seNR0OQA8oLK7RqqCdXJ2/lmyuvBsSQkkmy4JGBM6gHCkjopXpGHHYxLtaTddChyMDiDGIz2QJheXrJSFuXNNlwKMGgEQjtLbXi91Wx6UnsajpkuBCxAAMRFmZpTJpWXnMywMRyEAwhES8Zg0735GD/myrQsmCgEQEyXgC8iqwmVybuES/WvA7giAsL2epkqpfflPEu5oMF0KXIYAiImWl5Ijl5ddINMySkyXAgyJAAjbikfD0rjzcWk9sElt8Ge6HLgQARCT5azceXJRyUq9jyBgR6wChi111ezVc/3UFi8A4DT7O47oFcNqy5hFLBKBDdEBhK3EeoNSv+1R6ajYYboUeAAdQEzV3oGXlV0gmUnppksB+hEAYRvtR3fo8BcPB02XAo8gAGKqpPpTZE3parqBsA0CIIxTw7y1mx+Q7tp9pkuBxxAAYaIbqBaJZNANhGEEQBjVUblL6jY/IPFIyHQp8CACIExQC0MuLT1f5ueUmy4FHkYAhLEVvvXbHpH2w1tNlwIPIwDCpAU5s3UQTA2kmC4FHsQqYEy5UPMxqd70R4l0NZsuBQCMOdRZKbU9jXLVtItkZuY00+XAY/ymC3AT1Uy95ppr5Lrrrjvte/fcc4/k5eVJdXW1eJVlJaRp9zNy5MmfEP4AQG10HwvJY1XrZXPjTklYCdPlwEMIgBPI5/PJb37zG9m8ebP84he/6L/96NGj8sUvflHuvvtumTlzpnh1oUfFup/rjZ2Fv+QA4CQ7W/fIo5XrpCvSbboUeAQBcILNmjVLfvSjH8kXvvAFHfxUV/DWW2+Va6+9VlauXClvfvObJSsrS0pLS+X973+/NDe/0Ql74IEHZPny5ZKeni6FhYW6mxgMOn9LlI7KnXLose9LT+MR06UAgG019rbIAxWPy+HOY6ZLgQewCGSS3HDDDdLR0SHvfOc75fbbb5fXX39dli1bJh/+8IfllltukVAoJF/60pckFovJs88+K3V1dVJeXi7f/e535cYbb5Suri7ZsGGDvq8KjI5d6LH1YWk/ss10KcCgWAQCu1qcO18uKV0tSX6m6mNyEAAnSWNjow58ra2t8uCDD8ru3bt1oHvyySf776PmA6qO4f79+6W7u1tWr14tFRUVMnv2bHG6UEu1VG/4nUS6W0yXApwRARB2lp+SK9fMuEQKUvNMlwIXYgh4kpSUlMjHPvYxWbJkie4G7tq1S9avX6+7eX2XxYsX6/sePnxYzj33XFm7dq0eAn7Pe94jv/rVr6StrU2cqO3wFjn61E8IfwAwDm2RDnm44knZ037IdClwIXrLkygpKUlfFNXhe/vb3y533XXXafebNm2aBAIBWbdunbz44ovy1FNP6QUjX/nKV/SCkrlznXF0UCIe03v7tR182XQpAOAKMSsuG+q3SGOoWe8ZmOQPmC4JLkEHcIqsWrVKzwOcM2eOLFiw4KRLZmZm/yriSy65RL75zW/KK6+8IikpKfLwww+LE0R7OqRi3c8IfwAwCfZ3HJFHj62TrqjzFwbCHgiAU+STn/ykng948803y9atW/Wwr5oP+KEPfUji8bju9N15552ybds2OXbsmDz00EPS1NSkh5DtLthwWI787YcSaq40XQoAuFZzb6s8VPGEVAfrTZcCF2AIeIpMnz5dNm3apFf+qi1hwuGwXuxx/fXXi9/vl5ycHHnhhRfkhz/8oXR2durvff/739fbxthZ894XpGHHX9nbDwCmQG88LH+rWi8XFJ8rKwqXmi4HDsYqYIxJIhaRmpf+JJ2VO02XAowZq4DhZPOyZ8mV0y6SZH+y6VLgQHQAMWrhrmapev4+CbfXmS4FADzrSFeVtIU75dqZl0leSo7pcuAwzAHEqHRV75Ejj/+I8AcANtoqpirI38kYHQIgRqxl3wY59vxvJBEJmS4FAHBCJBGVJ6qekz1tB02XAgdhCBjDsqyE1G/7s7Tu32i6FADAIBJiyYaGrdIe6ZSLS1bpbcWAoRAAMexij+qNf5Cu6tdNlwIAGMZrbfv1XoFXT18jyZwjjCEwBIwzivV26c2dCX8A4BwV3dXy58p1Eoz2mC4FNkYAxKDCHY1y5Im7JdRSZboUAMAoNYfb5OHKJ6W515lnymPyEQAx6MkeR5+8W6LdraZLAQCMUTAWkj8fWyeV3TWmS4ENEQBxkvajO6TymV9KnJW+AOB40URMnqx+Qfa2HzJdCmyGGaLo1/Ta09K46wnTZQAAJpAllrxQv0UfI7eycJnpcmATBECIlYhL7eYHpf3wFtOlAAAmyZamXdIbC8tFJSvZJgYEQK9LxGNSvfH30lW123QpAIBJ9mrbPt0JvGLaheL3MQvMywiAHpaIheXYc/dKsJ7d4wHAKw50HtUh8E0zLpUk9gr0LOK/R6lFHhVP/5LwBwAedCxYK49VrZdwPGK6FBhCAPTwBs+h5krTpQAADKkPNcmfjz0tPTF2ffAiAqDHRHs65OhT90hvW63pUgAAhrWG2+XRynXSzakhnkMA9JBId6sOf5HOJtOlAABsojPaLX859rR0R4OmS8EUIgB6RKSrWSrW3SPR7hbTpQAAbBkCn5EuQqBnEAA9cq7v0XU/k2iw3XQpAACbdwK7It2mS8EUIAC6XG97vV7wEevpMF0KAMDmVAfwz8eekU5CoOsRAF3e+dPhr7fLdCkAAIfojgV1J5AQ6G4EQJeKdLdIxTO/kHiY+RwAgNHpjvXoENgRoYHgVgRAl271ojZ5ZtgXADC+EMhwsFsRAF0m1tstlc/8gtW+AIBxC8Z65LGqZyXIZtGuQwB02fFulc/8Ss/9AwBgolYHP3bsWX1+MNyDAOgSiVhYKp/9b+ltqzFdCgDAZdoiHfK3qvUSiUdNl4IJQgB0gUQ8Jseeu5ezfQEAk6apt1WerHleYom46VIwAQiADmcl4lL9wm8lWH/QdCkAAJer7WmUdTUbJGElTJeCcSIAOphlJaR60/9KV80e06UAADziWLBW1te9JJZlmS4F40AAdCj1B6/25Qeks3Kn6VIAAB5zqLNSNjZsNV0GxoEA6FCNu56Q9sNbTJcBAPCoPe2HZFvTq6bLwBgRAB2o7fAWad79jOkyAAAet71lt+xvP2K6DIwBAdBhuusPSt3mB02XAQCA9kL9FqkO1psuA6NEAHSQcEeDVL3wW73yFwAAO0hIQq8Mbg23my4Fo0AAdIhYb5fe6DkR4TgeAIC9RBJRebzqOQlGe0yXghEiADpAIhaVY+t/LdFgm+lSAAAYVHesR56ofl6iCU4LcQICoCP2+vujhFqqTJcCAMCQmsNtsq5mIxtFOwAB0OYadjwmXVWvmS4DAIARqQrWycaGbabLwDAIgDbWeuBFadn7vOkyAAAYlb3th+TV1n2my8AQCIA21VWzV+q2PmK6DAAAxuTlxlekOlhnugycAQHQhsIdjVK98fcizKEAADiUJZY8XbNJOiJdpkvBIAiANhOPhqXqhXslEQ2bLgUAgHEJJyLyZPULEomzMthuCIA2U/vS/9MdQAAA3KAt0iHP1r0olmWZLgUDEABtpHnPc9J5jIO1AQDuUtldIztadpsuAwMQAG0i2HBYGl75m+kyAACYFNuaX9NBEPZAALSBaE+HVG9g0QcAwN2erX1ROiKdpssAAdA8KxGXqg2/02f9AgDg9jODn6rZILFEzHQpnkcANKx++58l1FRhugwAAKZEa7hDNjVsN12G5xEADWo/ukNa928yXQYAAFNqX8dhOdhx1HQZnkYANKS3rU5qX77fdBkAABixoWGrtIeZD2gKAdCAeCQkVS/cJxYbYwIAPCqaiMm62o0SS8RNl+JJBEAD6rY8JJGuZtNlAABgVGu4XV5sZD6gCQRAA/P+OipeMV0GAAC2sLf9kBzqZDHkVCMATqFId6vu/gEAgDe8UL+F/QGnGAFwilhWQmpe/D9JRHtNlwIAgP3mA9ZskrjFfMCpQgCcIs2vr5eexiOmywAAwJZawm2yrek102V4BgFwCoRaqqXp1adMlwEAgK3tat0rdT2NpsvwBALgJEvEIlK96Q/6yDcAAHBmlljyXN3LEk2wTdpkIwBOwVFvkc4m02UAAOAIndFuebFhh+kyXI8AOIk6q16XtoMvmy4DAADHHRVX0VVtugxXIwBOkmioU2pf/pPpMgAAcOzWMKEYO2dMFgLgJKl96U8SDwdNlwEAgCOF4r06BGJyEAAnQdvhrdJdu890GQAAOFpFd7Xs72ALtclAAJxgsd4uadj+F9NlAADgCi82bJdgtMd0Ga5DAJxgdVsflXiENyoAABMhkojKxoZtpstwHQLgBOqq2SudlTtNlwEAgOuGgo92VZkuw1UIgBMkHg1L3ZYHTZcBAIArqS5gOB4xXYZrEAAnSOPOxyUabDddBgAArtQTC8mWJkbZJgoBcAL0NFdK64FNpssAAMDV9rQf4qzgCUIAHCd1xm/tyw+IWJbpUgAAcD21N2A8ETddhuMRAMep+fX1Em6vM10GAACe0B7plB0tr5suw/EIgOMQ7mySpteeNl0GAACesrN1j7SGmXc/HgTAMbIsS2pfvl+sRMx0KQAAeErCSsjGevYGHA8C4Bh1HN0hPY0cTwMAgAl1oUY51FlpugzHIgCOQSIWloZXHjNdBgAAnra58RWJMhI3JgTAMWjavV5ioU7TZQAA4GndsR7ZyYKQMSEAjlIk2CYte58zXQYAABCRXa37pDPSbboMxyEAjlLDjsfEitNuBgDADuJWXF5q3GG6DMchAI5CsPGodFZyDA0AAHZS0V0t1UH25B0NAuAotn2p3/ao6TIAAMAgNjVs19vDYGQIgCPUfmSb9LZWmy4DAACc4YSQ3W0HTJfhGATAEYhHw9K483HTZQAAgCFsb35NwvGI6TIcgQA4As27n2HbFwAAbC6SiMorbAszIgTAYUS6W6Vl7wumywAAACOghoG7oz2my7A9AuAwGnb8lfN+AQBw0LYw25pfNV2G7REAhxBqqZbOY7yJAABwkgMdR6Ut3GG6DFsjAA6h8dUnTZcAAABGyRJLNjexb+9QCIBn0NNUKd01e02XAQAAxqCyu0bqe5pMl2FbBMAzoPsHAICz0QU8MwLgIIKNRyRYx2aSAAA4WX2oSSq6OMRhMATAQTTufMJ0CQAAYAJsbX5VH+eKkyWd8rXnddcdlJ7GI6bLwDj96s+b5eltB+VoXaukJSfJioXT5XM3XS5zpxWcdl/1F8PH//Mh2fhqhfzoM++QtectPOPj/vShF+WJl/dJfUuXJCcFZOncUvmXd18q5yyYpr8ficbka//zlKzffliK8jLltg+slYvPnt3/+3/92Fapb+mUf79l7SQ9cwDAQK3hdqnorpa52bNMl2IrdABP0biL7p8bbNtXLTdfs0L++PV/kF9+6d0SjSfko3c9ID290dPu+7sndohPfCN63Dll+Tq8PfTtD8hvv3qTTC/KkY9+9wFp7Ty+6ej961+VPUcb5A9fv1nefeVy+dI9j/X/y7O6sUMefO41+Zf3XDrBzxYAMJQdzbtNl2A7BMABumr2Sqi50nQZmAC/+OK75IbLz5YFM4tk8ewSueOj10tdS5fsqWg46X77Khvlvse3ye0fuW5Ej/vWNUt0R29WSZ5+7C++70rpDkXkQNXxlWZHalvlqlXz9fduftMKae0KSVtXSH/v9nufls/9/WWSlZ46Cc8YAHAmzeE2vSoYbyAADtC4i5W/btUdCuvr3My0/ttC4ah88Z7H5CsfWKuHa0crGovL/c++KtkZqXJWebG+TV3vOFAjvZGobHq1QorzMiU/O13+ummvpCYH5JohhpcBAJOHLuDJmAN4QmfVbultZaWQGyUSlnzn98/JykXTZeGsov7bv/uH5/TcwKtXLxjV4z33ymH5158+pkNecV6WHmLOz87Q37vx8rPlwLEm+bsv3St52eny/U+9TTqDvfKThzbJb/79vfLj+zfK4y/vl1mluXL7h6+T0oLsCX++AIDTNfa2SFV3rczKmm66FFsgAJ7Q9OpTpkvAJPnWfc/IoepmPWevz/odh2TznmPywLfeP+rHu2BJuTx4x/v10O4D61+TL9z9F/njN94nhbkZemHIbR+85qT73/bLJ+R9167Sw83Pbj8kD95xi/z6sS3y7d+tlx9+5h0T8hwBAMPb3rKbAHgCQ8BqeLB2v/S21ZouA5Pgjvueked3HpZff/m9Ujag27Z5T5VUNbbLxR/7iZz7gR/oi/K5H/9FPnjH/xvyMTPSkqW8NF/OXTBdzx0MBPzy0POvDXrfLXuOyaGaFvmHN62QrXur5bJz5+rff/2FZ8nWfVUT/GwBAENpCDVLTbDedBm2QAdQTQ7d85zpEjDB1MrbO3/7rDyz/ZAeep1ZknvS9z/8tgvkXVcsP+m2G//9Pr2o48qV80f1/0pYlkRi8dNuD0diuvt418ffIgG/X+KJhFjW8dXGsXhCD00DAKbW9ubdMiOzTLzO8x3AUGuNBOsPmi4DE0wFr7++uFeHr8y0FGluD+qLmrenqEUfaj7gwIsyrTD7pLD49i/+Wu8nqKgtZH74pw2y61Ct1DZ3yutHG+S2Xz0hjW3dct0Fi06r4eePvqw7fkvmlOqvVy6aoR9r/7Em+eO6V/T8QwDA1KoLNUpdT6N4nec7gC17njddAibB/3tml77+0J1/Oun2b33kOr09zEgdrWuT7p7jK4gDfp/eWPrPP96j5//lZaXJ2fPK5L7bbtLbvgx0sKpZnty8Xx741i39t117/iLZurdKPvCt/5M50wrku594yzifJQBgLHa17pVpGSXiZT7Lw+ejRIPtcuCRO0WshOlSABiw8bxVpksAYIBPfPL3894quSk54lWeHgJu2beB8AcAgMdYYsmrrfvFyzwbAOORXmk7tNl0GQAAwIADHUekN358io8XeTYAth16WRLRXtNlAAAAA2JWXPa2HxKv8mQAtBLx48O/AADAs3a3HZC4R6eCeTIAdlTslFhPh+kyAACAQT2xkBzurBQv8mQAbNnL1i8AAEDktdZ94kWeC4DddQc49g0AAGjN4TapDTaI13guALYeeNF0CQAAwEZea/PeljCeCoDRUKd0Ve8xXQYAALCRyu4aCUZ7xEs8FQDbD29l42cAAHDaxtBe2xLGMwFQnXjXdmiL6TIAAIAN7e04LAkPNYk8EwCD9Qcl2t1iugwAAGDTLWEqu2vEKzwTANsOvmy6BAAAYGN7PDQM7IkAGOvtkq7q102XAQAAbKwmWC9d0aB4gScCYPvhbfr4NwAAgKEWg+xrPyxe4PfG4o/NpssAAAAOsN8ji0FcHwB7Gg5LpKvZdBkAAMABgrGQVAXrxO1cHwBbWfwBAABGYX/HEXE7VwfAWG9Quqp2my4DAAA4yLHuGgnHI+Jmrg6AHRWviJWImS4DAAA4SNxKyJGuY+Jmrg+AAAAAo3Wwo0LczLUBMNLdKqFmd6d3AAAwOepCjdLt4j0BXRsAOyt36R19AAAAxuJgp3u7gK4NgB0VO02XAAAAHOwQAdBZwp1N0tvmnQOdAQDAxGsNd0hLb5u4kSsDIIs/AADARDjg0i6gKwNgZyXDvwAAYPwOd1boY2XdxnUBsLetVsIdjabLAAAALjkariHkviNlXRcAO/TqXwAAgIlxtLtK3MZ1AbCT1b8AAGACVXRVi9u4KgCqjZ8j3S2mywAAAC7SGe123WpgVwVAhn8BAMBkONrtri6gqwJgV9Vu0yUAAAAXOtrlrnmAfjdt/szwLwAAmAyt4XbpjHSLW7gmAHbV7DVdAgAAcLGjLuoCuiYAdhMAAQDAJKpw0TxAVwTAeDQsPY1HTJcBAABcrCHULD2xkLiBKwJgsO6AWIm46TIAAICLWWJJVbBO3MAVAbCrdp/pEgAAgAdUEwDtg/l/AABgKlQH68WyLHE6xwfAUGuNxEKdpssAAAAe0BsPS3PY+aeCOD4A0v0DAABTqarb+cPAjg+AzP8DAABTqdoF8wAdHQBj4aCEmitNlwEAADy2HUwkHhUnc3QADNYeEHHBREwAAOAcCUlIbU+DOJmzA2DDIdMlAAAAD6py+DCwswMgp38AAAADqgmAZsR6uyTS2WS6DAAA4EGd0W7pjgbFqRwbAHsaj5ouAQAAeFhdj3MbUY4NgEECIAAAMKg+1ChO5dgA2NPA/D8AAGBOfYgO4JSKR3qlt73WdBkAAMDDWsMd+mg4J3JkAOxpOsr+fwAAwLh6h84DdGYAZP4fAACwgXqHDgM7NAAy/w8AAJhX1+PMhSCOC4CJeFRCLVWmywAAAJDm3jaJJWLiNI4LgKHmY2Il4qbLAAAAEHUucGOoRZzGcQGQ+X8AAMBOGnqbxWkcFwAZ/gUAAHbS3NsqTuO4ANjbVmO6BAAAgH5NBMDJFQv3SDTYbroMAACAfl3RoOM2hHZUAKT7BwAA7Loa2EmcFQBbCYAAAMB+mh02DOywAMj5vwAAwH6aCICThyFgAABgR80EwMmRiEUl3OnM8/YAAIC7dUa7JRyPiFM4JgD2tteJWAnTZQAAADi+C+icAMgCEAAAYGMtYeesBHZOAGxjAQgAALCvtnCnOIWDAiAdQAAAYF/tEQLghLKshPS21ZkuAwAA4Izawh3iFI4IgNHuVrHiUdNlAAAAnFE4EZFQrFecwBEBMNLVYroEAACAYbVFnNEFdEQADHc1my4BAABgWO0OWQjiiAAYIQACAAAHaKMDOHEIgAAAwAna6QBOHAIgAABwgjaHbAXjd8IWMGoVMAAAgN0FYz0STdh/5xLbB8BosF2sRNx0GQAAACPSFQ2K3dk+ADL8CwAAnKSLADh+BEAAAOAkXQTA8WMTaAAA4CTdBMDxowMIAACcpIsAOH4EQAAA4CTdBMDxi7AFDAAAcJAuAuD4xCO9YsXtv5cOAABAn1C8V2I238LO1gEw1ttlugQAAADXDQMTAAEAACZYV4wAOGaxEAEQAAA4TzDaI3ZGAAQAAJiEeYB2Zu8AyBAwAABwoJ4YAXDM6AACAAAnChEAx44OIAAAcKIQQ8BjRwcQAAA4UYgO4NjRAQQAAE7UGw+Lndk6AMZ7u02XAAAAMGrheFgsyxK7sm0AjIV7xLL5MSoAAACDSYglkYR9j7O1bQCMM/wLAAAcrNfGC0HsGwAjIdMlAAAAjFlvPCJ2Zd8AGLVvagYAABhOlCHg0UtE7b16BgAAYCjRREzsysYBkA4gAABwrigBcPToAAIAACeLEgBHL04ABAAADha18RzAJLGp7uxs6V60QvyxmPjjUfFHI+Lru0TC4ov0ij9m39U1AADA26I27gDaNgDWpAdkT45qUKacuGSedh+f+CTJFzhx8R+/iF8C6olZPglYIgHLEn8iIYGEJQF1rQNlXPzxmPhjUfHFVLiM6mDpj4bFF+09HjDj9v2hAQAA+4vSARy9uDX8KSCWWBK1YvoyJJ+IToXqktx3Y98NaWf4LT5J9iedCJXHA2ZABU7Lp180HS5PBEsdMOMJ8SfiJzqWKlyqS2RA5zLc37n0WYkxvCIAAMBJonQARy9m+EWzThzhMuwgs//E5aRXMunEZfBwGdDdygGdS9W11MHSdzyWqm6lpTqWVn+wDPR3LQd2LvuGxHvFr1ZNRyLiE/ueOwgAgJfEhmtQGWTfADiCDqBTxa2EvoQlOrJweVIrM3lgG/M0bwTLvnCpupbHh8X7hsT7h8MTiRPD4W8Mifv7hsRV9zIyYEg8Zt82NgAAdhSlAzh68YR7A+BkB+dhw/OgQ+IqaaaeuMiZ51v6AyeGxFXH0n98ruXAIXEdMFWwPB4uA6eEy/6FPNHw8YCphsT5WQMAXChu42aWfQMg8+RspX++5XCLYwaGSxnZfEu/CpL+gCT7AhJQvz7RudTD4n1dy/45lye6lnq+pQqXKlieCJgDhsSPz7lU8y0ZEgcAmGHZ+CPItgEQ3pGQhEQSCYmMdEj8pHdt35B4+hnnWyb7ji/mCagOpupknhYuBy7kUdfxN0Jl/I0h8eOLeNiCCAAw8uaJXdk2ANr5RYPT5luOIKwNOt+ybwuiwakh8b5w2b9K/ES4VB3LJB0s++ZbquFw1b08vg2R3nboxHxLFSZ1sOxbKR5nviUAuIFl4xYgARAwMt8ybcRbEOlV4ye2IDo+39KSpISI3+obEk+cskr8+BZEPhUu9d6WbEEEACZYNs4y9g2ANk7NgC22IBp0vuXQWxD59ZD4iVXiJ+Zb9u1veeoWRCpYJqm5ln0rxfsW8pxYzKPmXB5fKR4WUeHSxn/RAYAJlo3/XrRtAAQw8RJq+6ExbUEkY9qCqD9cDphveTxc9q0QP9MWRJH+YMl8SwBOZdm4mWXbAGjn1AxgjEPiA8PlmLYgGnjkY99Cnjc6l8c3Te8bEh/syMfjHUs9NB4JT+jzBwAnZRkbB0AAmNwtiADAqx3A0wZ5bMPGLxoAAICTO4C2DYB2ftEAAACGY+ckY9sAeHw8BwAAwJkCPvvGLNtWZucXDQAAYDjqBCq7sm3KsvOLBgAA4ORmlm0rC/htWxoAAICjm1m2TVl2ftEAAACGo05fsivbVkYABAAAThawcZaxbQBUO/8DAAA4VYAO4OgF/ARAAADgXAEbZxn7BkAbp2YAAAAnZxnbVmbncXMAAIDh+G2cZQiAAAAAkyDZnyR2ZdsAmOJPNl0CAADAmKX6U8SubBsAUwP2fdEAAACGkxqwbzOLAAgAADAJUugAjh4BEAAAOFmqjbOMfQOgjVMzAADAcOgAjkFqINV0CQAAAGPGHECXtU0BAACcnGX8dt47x2/jHbQBAADOxC8+Sbbxlna2TljMAwQAAE6UYuPun/0DoM1fPAAAgMGk2Xwtg60DoN1fPAAAgMFkJKWJndk6AGYmpZsuAQAAYNQybJ5hbB4AM0yXAAAAMGoZNs8wtg6Adk/PAAAAThzFtHUAzEy294sHAADgxCaWvQOgzdunAAAAg6EDOA4EQAAA4EQZBED3vngAAACDoQM4Dkn+AHsBAgAAR0nxJ0uSP0nszNYBUKELCAAAnCTTAVPYbB8A7d5CBQAAGCg7OVPszvYBMCc5y3QJAAAAI5aTki12Z/sAmOuAFxEAAKBPbor9m1e2D4BOSNEAAAB9cpLtn11sHwDpAAIAACfJdUB2sX0AzE7OEp/4TJcBAAAwLL/4JItFIOMX8PkdsZoGAAAgKzlTZxe7s3+FzAMEAAAOkeOABSCOCYC5bAUDAAAcIMcBC0CcEwDpAAIAAAfIpQM4cQiAAADACfJScsQJHBEA81JyTZcAAAAwrILUPHECRwRAtQo4xZ9sugwAAIAzUlnFCVvAOCYA+nw+yU+lCwgAAOyrwCHdP8cEQKUwNd90CQAAAGdUSAD09osKAAC8p8BBWcUxAdBJLyoAAPCegjTnZBXHBMBCB72oAADAewpSnJNVHBMAk/3JksOJIAAAwK47lgScs2OJYwKgwjAwAACwowKHZRRHBUAWggAAADsqdNhuJY4KgEVpBaZLAAAAOE2xwzKKowJgSXqh6RIAAAAcn1EcFQAzktIlK8kZR6wAAABvyErK0BnFSRwVAJVShyVsAADgbsUOzCYODIBFpksAAADoV5JGAJx0JQRAAABgI6UOzCaOC4BFafkS8DmubAAA4EJ+8TtuBbDiuCQV8AUct9cOAABwp8K0PEnyJ4nTOC4AOrXVCgAA3KckzZmZxJEBkHmAAADADkodmkkcGQDLHPpiAwAAd5meUSJO5MgAmJWcKdnJbAgNAADMyUvJkczkDHEiRwZAZXpGqekSAACAh013aPdPIQACAAB4LIs4OAA6N3UDAADnm04ANDMPMCc5y3QZAADAgwpScyU9KU2cyrEBUJmRWWa6BAAA4EHTHdz9c34AzCAAAgCAqTedAGjOjMxS8YnPdBkAAMBDfOIjAJqUFkiVwtQ802UAAAAPKUzNk9RAijiZowOgMjNzmukSAACAh8zKmi5O5/gAWO6CHwIAAHCOchdkD78bDmFO9Tu7DQsAAJwz/aw0rUiczvEB0O/zu6IVCwAA7G9W5jTx+Zy/ANXxAVCZTQAEAABTYHbWDHEDVwTAWZnTxc92MAAAYBL5xeeaxaeuCIBqKXZZRrHpMgAAgIuVZRQ7fvsXVwVAN7VkAQCAPZVnuidruCYAlhMAAQDAJCp30ZoD1wTAvJQcyU3JNl0GAABwoZzkLMlPzRW3cE0AVBgGBgAAk2Fu9ixxE1cFwHnZ5aZLAAAALjTfZRnDVQFQnQqSlZRpugwAAOCy4d/i9EJxE1cFQGV+jrsSOgAAMGuey7p/Lg2As02XAAAAXGSeC5tLrguAxWkFulULAAAwIcO/aQXiNq4LgApdQAAAMBHmuzRTuDMAunCsHgAATL35Ls0UrgyAhWn5emNoAACAscpLydGZwo1cGQDd3LIFAABTY55Lu3+uDoALsgmAAABg7BblzhG3cm0AzEvNkZI0d23aCAAApkZZerHkung6mWsDoHJW7jzTJQAAAAc6y+UZwtUBcEHOHEnyBUyXAQAAHCTJF3D1/D/XB8CUQLLMzZ5lugwAAOAgc7Nn6QzhZq4OgMpZufNNlwAAABzkLA9kB9cHwOkZJZKdnGm6DAAA4ADZyZk6O7id6wOgz+dz/UROAAAwMRblzNXZwe1cHwCVRbnzxCfu/2ECAIDxOcsjTSO/V9q5MzJKTZcBAABsbHpGqWSnZIkXeCIAKovz3D+hEwAAjN2yvIXiFX4vLenOSEo3XQYAALChrKQMmZM9U7zCMwHQ7/PL0rwFpssAAAA2tCRvgc4KXuGdZ+rBHy4AABie3+fXGcFLPJWG1BCw2492AQAAozMvu1zSk9LESzwVAJWz8xeZLgEAANjI2R7MBp4LgKXpRVKcVmC6DAAAYAPFaQU6G3iN5wKgV5M+AAA43bI8b2YCTwbA+dmzJS2QaroMAABgUFogVebnzBYv8mQADPgDnlvtAwAATrYkb4Ek+QPiRZ4MgMqy/EUSYEsYAAA8KeALyPL8s8SrksSjMpPSZWHOXNnXcdh0KQDgSf++9jPSWtt82u1X3HyN3Py1D8n3b/mWHNy696TvXfb3V8v7vnHrGR/zn5e8b9Db3/mFm+XaW98m0UhUfn/br2TXs9slpyhP/3+WrDm7/35P/c9fpbWuRW667QPjem6wv7Ny53lu65eBPBsAlRWFS2R/xxGxxDJdCgB4zpfvv10S8UT/17UHq+VHt35bVl1/Yf9tl77nKnn7p9/d/3VKesqQj3nXCz896evXN+yS3932K1l57QX6641/elYq9xyVL/7vN2X3hl3y63/9qXx34z3i8/mkubpRNt6/Xr78wO0T+CxhRz7xybkFS8TLPB0Ac1Ny9BnBR7qOmS4FADwnuyDnpK+f/NVfpLi8VBad/8YHc0paquQW5434MU+9r+r0LbpwqRTPKtFf1x2ulXOvWi3TF86Uolkl8tD3/ijdbV26lj9+8zdy4+dvkvSsjHE/N9jbvOxZkpOSJV7m+UlwKwqXmi4BADwvFonJ5r9slDXvvEJ34/ps+esm+fzFH5P/ePuX5OEf/J9EQuERP2Znc4e89vxOueRdV/TfNnNxuRzasV8ivRHZs/FVHRiz8rNl8182SXJqsqx80/kT/txgPyv47Pd2B7BvA8iZGWVS3VNvuhQA8Kydz2yTUFePXHzj5f23XfC2NVIwvUjySvKken+VPPz9/5WGo3Xyz3d/bkSP+dIjL0haZtpJoe6Sd14hNfuPyTff9kUd/D7yX/8iPR1B+cvdD8j/d99t8ugP/yTbHn9Zdwzff8dHJb+UgwPcZmZmmRRxIAQBUFlRuIwACAAGvfjgc7LssnMlryS//7bL3nt1/69nLCrX3boffuhOaTrWoIeKh33Mh56XC952iSSnvjFvMJCcpBd+DHTfv/9CrvrH66Rqb4Xsema73PbwnXoxyJ/u+K187MefnbDnCHtYUUD3T/H8ELAyI7NUStIKTZcBAJ7UUtMke1/aLZe8+8oh7zf3nPn6uvFYw7CPeXDbPt0tvHSYx9y/+XWpPVQtV73vWjmwZa8su/xcSc1Ik9XXX6S/hvtG/WZklpkuwxYIgCcwHwAAzHjx4RckuyBXll+xcsj7Ve2r1NcjWRSy6cHnpHzZXJm5+MynPETDEfnf2+/V28r4A35JJBISj8X19+KxmP4a7kL37w0EwBPmZM2U/JRc02UAgKeokPXSQ8/LxTdcJoGkN05kUMO8j93zsFS+flSaa5r0at57/+3nsvC8xTLzrPL++339LV+QV9ZtPekxQ909suPJLcN2/x772SNy9uUrpHzpHP31/JWLZOe6rVK9/5g894d1+mu4R0Fqnt75A8cxB/AEtepsddFyebp2o+lSAMAz9r20W2+8rFb/DqTm6qnvPfvbJyQcCkt+WYFezPGWj99w0v3UMK8KfANt+9vLYlmWnP/WNWf8/9YcqJLtj7+s5/v1WXXdBXrY9z//8T+kdO40ufV7n5yw5wnzzitaftIKc6/zWepPCTT1UjxY8YS0hNtMlwIAACaIWvX7rjnXmy7DVhgCHkD9y0D9CwEAALjH+Xy2n4YAeIo52TNZEQwAgEuoz/TyrBmmy7AdAuAgzi8+x3QJAABgApxffK7pEmyJADiImZnTZFr68XMjAQCAM6nPcnXyB05HADwDuoAAADjbeXyWnxEB8AymZah/NUwzXQYAABiDGRllMj2D0bwzIQAO4YIi/uUAAIATXcjcvyERAIdQnF4o87Pf2HEeAADY34Kc2fozHGdGABzGhSUrJeB743giAABgXwGfXy4oovs3HALgMLKTM2V5/lmmywAAACOwLP8syU7JMl2G7REAR2Bl4TJJD6SZLgMAAAwh1Z8iqwqXmS7DEQiAI5ASSOaIOAAAbE59VqcGUkyX4QgEwBFanDdfClJzTZcBAAAGkZeSI0vzF5ouwzEIgCPk9/nlopJVpssAAACDuKhkpf6sxsjwSo3CrMxp+gIAAOxjZkaZzM6aYboMRyEAjtLFJavELz7TZQAAAB1k/LKmdLXpMhyHADhK+am5six/kekyAACAiCwvOEt/NmN0CIBjcF7ROZKRlG66DAAAPC0rKUNWs0vHmBAAx7gtzMUlK02XAQCAp6mh32R/kukyHIkAOEYLcubI9IxS02UAAOBJ5ZnTZW72LNNlOBYBcBwuLT2PJecAAEyxJF9ALik9z3QZjkZ6GQc16XRFwRLTZQAA4CkrCpdKDuf9jgsBcJxWFp4tOcm8CQEAmAq5KdmyomCp6TIcjwA4Tkn+gFxWdr7pMgAA8Mz0q4A/YLoMxyMAToCZmdNkQc5s02UAAOD6BZjqMxfjRwCcIGtKVktaINV0GQAAuFJGIE0u4cSPCUMAnCDpSWlyaSlDwQAATIZLy86n0TKBCIATaH5OuczLLjddBgAArjI/u5w9/yYYAXASJqfyLxQAACZGuh76Zc+/iUYAnGAMBQMAMHFU+FOfrZhYBMBJGwqmVQ0AwHioz1L1mYqJRwCcJKoLyFAwAABjoz5DGVGbPATAScJQMAAAY6e2fGHod/IQACcRq4IBABg9dbiC2vQZk4cAOMkuL7tAspIyTJcBAIAjZCdnMoI2BQiAkyw1kCJXTV8jPvGZLgUAAFtTn5VXT1ujPzsxuQiAU2B6RomsLFxmugwAAGxtVeEyKcsoNl2GJxAAp8jqorOlNL3IdBkAANiS+oxcVXS26TI8gwA4Rfw+v6ydtkZS/MmmSwEAwFbUZ6P6jFSflZgavNJTKDslSy4rY2IrAAADqc9G9RmJqUMAnGJqWfui3HmmywAAwBYW5sxhyxcDCIAGXFq6WnKTs02XAQCAUeqzkC1fzCAAGpDsT5ZrZlwqSb6A6VIAADBCfQa+acZlkhJgbrwJBEBDitLy+VcPAMCzLiu7QArT8kyX4VkEQIPOypsnS/IWmC4DAIAptTRvoSzKnWu6DE8jABp2SclqKU4rMF0GAABToiStUNaUrjJdhucRAA0L+I/PgUgLpJouBQCASaU+694041IJMAfeOAKgTQ6+Xst5wQAAt5/zO32NZCVnmi4FBED7mJk5Tc4rWm66DAAAJu1I1FmZ00yXgRMIgDaysnCZzM6aYboMAAAmVHnmdFlVyDm/dkIAtBGfzydXTbtY8lJyTJcCAMCEyE/JlbXTL9GfcbAPAqDNpAZS5PqZl0uqP8V0KQAAjHvRx/Uzr2CzZxsiANpQbkqOXDvjMvHz4wEAOJTf59efZTkpWaZLwSBIGDY1PbNULi07z3QZAACMyWWl58u0jBLTZeAMCIA2pk4JOSd/sekyAAAYlXMKFsvivPmmy8AQCIA2d1HJSr16CgAAJ1CfWRcVrzRdBoZBALQ5tWrqmhmXSEEqB2YDAOytIJUVv05BAHSAZH+yXkWVHkgzXQoAAINSn1HXz2DFr1MQAB10XNx1My+XJM5PBADYTLI/Sd4860rJZsWvYxAAHaQ0vUgfou3nzGAAgE2oLcvUdi/FaQWmS8EoEAAdpjxrhlwx7ULTZQAAoF057UJ9nj2chQDoQIty58mFxStMlwEA8Di12ndh7lzTZWAMCIAOtaJwKXsEAgCM7vV3buES02VgjAiADt8jcEHOHNNlAAA8Rn32sNefsxEAHUzts3TltIuYewEAmDIzM8v0Zw97/TkbAdDhAicO2y5JKzRdCgDA5dRnjfrMUZ89cDZ+gi7af4nTQgAAk6UoNV/eMusqfTgBnI8A6BJpgVR526yrJS8lx3QpAAAXHvGmwl9qIMV0KZggBEAXSU9Kk7eXr5XclGzTpQAAXEI1Ft4662r9GQP3IAC6TEZSurx91lrJSeY4HgDA+KjPEjW6pD5b4C4EQBfKTM6Qt5Wv1ecHAwAwFllJmfqzRH2mwH0IgC6lwt/bZq2VrCT+4AIARidTjSbRSHA1AqCL5aRk6X+90boHAIxUeiBNf3aozxC4FwHQ5dSCEDUnkBAIABjRPPLytewo4QE+y7Is00Vg8nVEuuSvx56V7ljQdCkAABtSU4ZU54+dJLyBAOgh3dGg/LXqWR0GAQA4abUvc/48hQDoMT2xkDxWtV5aw+2mSwEA2IAa7lVbvbDa11sIgB7UGw/L36rWS1Nvq+lSAAAGFabmy1tnXcUmzx5EAPSoSDwqj1c/J/WhJtOlAAAMKE0vkjfPvJLj3TyKAOhh0URMnqrZINXBOtOlAACm0IyMUrlu5hWS7E8yXQoMIQB6XNyKy9M1m6Siu9p0KQCAKTA3e5ZcPW2NJPkDpkuBQQRASMJKyMaGbbK3/ZDpUgAAk+js/EWypmS1+Hw+06XAMAIg+m1vfk22Nb9mugwAwCS4sHiFrChcaroM2AQBECfZ135YNtRvkYTwtgAAN/D7/HJl2UWyMHeO6VJgIwRAnOZYd42sq9kkMStmuhQAwDik+JPl2hmXyYzMMtOlwGYIgBiU2iPwiern9cbRAABnnuv7lplXSmFavulSYEMEQJxRVzQoj1c9J22RDtOlAABGIT8lV94860qOdsMZEQAxpHA8ovcKrO1pMF0KAGAEZmaUyTUzLmWDZwyJAIgRbROzqWG77Gk/aLoUAMAw27xcXLJKL/wAhkIAxIjtaTuog2BCEqZLAQAMoALfpaXnyZK8BaZLgUMQADEqtT2Nsq5mg/TGw6ZLAQCISFogVa/0nZZRYroUOAg9YozK9IwSeeec66UwNc90KQDgeQWpefrvZDuGvw9+8IP6xJHvfOc7J93+yCOPcBKJDRAAMWpqVdnfzb5W5mXPMl0KAHjWnKyZcsPsa2290jctLU3uuusuaWtrM10KTkEAxJgk+5PkmumXynlFy02XAgCes6rwbD3sq/4utrNrrrlGysrK5Nvf/vYZ7/Pggw/KsmXLJDU1VebMmSPf//73p7RGryIAYsxUC3910XL9l5DabR4AMLlS/Sly3YzL5fzicxwxjBoIBOTOO++Uu+++W6qrq0/7/vbt2+W9732v3HTTTfLaa6/JN77xDfnqV78q9957r5F6vYQAiHGbmz1Lz0EpSmW3eQCYLMVpBfKuOdfLnOyZ4iQ33nijrFixQr7+9a+f9r0f/OAHsnbtWh36Fi1apOcNfupTn5Lvfe97Rmr1EgIgJkRuSraei8IWBAAw8ZbmLZS/K3+TZKdkiROpeYD33Xef7N2796Tb1deXXHLJSbeprw8ePCjxeHyKq/QWAiAmTMAfkMvLLpCrp62x/bwUAHAC9Xfp2ulr5LKy8/XfsU51+eWXy3XXXSdf/vKXTZeCE/iUxoRbmDtHitLy5enajdIa5hxhABjreb5vmnGp5Kfmihuo7WDUUPBZZ53Vf9uSJUtk06ZNJ91Pfa2Gg9X8QUweOoCYFOovrBtmXyeLcuaaLgUAHGdhzhy5cc51rgl/yvLly+V973uf/PjHP+6/7fOf/7w888wzcvvtt8uBAwf0MPFPfvIT+cIXvmC0Vi/gJBBMun3th2VTwzaJWcznAIDhhnzXlKyWxXnzxenUgo729na98XOfiooK3QGMRCLSFz/UNjBf+9rX9Ly/adOmyac//WkC4BQgAGJKtEc65dnaF6Wpt9V0KQBgSyVphXL19DV6UR0w2QiAmDIJKyHbm3fLKy2viyW87QBA8YlPVhUuk1VFZ4vfx8wsTA0CIKZcfahJ1te+JJ3RbtOlAIBROclZctX0i6Usvdh0KfAYAiCMiCaisqlhu+zvOGK6FAAwYlHuPLmkZLWkBDhJCVOPAAijjnZVyQv1W6Q3HjZdCgBM2XFuas/UeTnlpkuBhxEAYVxPLCTP122WY8Fa06UAwKQqz5yuw19mcobpUuBxBEDYxoGOo/JS4w66gQBcJy2QKpeUrpYFOXNMlwJoBEDYSijWKxsbtsmRrmOmSwGACTE/e7YOf+lJaaZLAfoRAGFLFV3VsrFhqwRjIdOlAMCYZCSly2Wl58uc7JmmSwFOQwCEbYXjEXm58RXZ13HYdCkAMCqLc+fLRSUrJTWQYroUYFAEQNhebbBBnq/fzL6BAByxr59a5DEjs8x0KcCQCIBwhFgipk8RebVtnz5RBADsJODzy7kFS2Vl4VJJ8ieZLgcYFgEQjjtTeFPDNqkO1psuBQC0WZnT5JLS8zjDF45CAIRjN5B+sWGHdMeCpksB4FFZSZmypnSVzM2eZboUYNQIgHD0sPArLXtkV+seiTMsDGBKh3uXyMrCZQz3wrEIgHC8jkiXvNiwnZNEAEw6hnvhFgRAuEZld40OgqwWBjDRVOC7qHgle/rBNQiAcBU1FLyn7aDsaNnNkXIAxi09kCari86WJXkLxO/zmy4HmDAEQLhSJB6VV1pfl92t+yVmxU2XA8BhknwBWV6wWFYULJWUQLLpcoAJRwCEqwWjPbK1+VU50HFULOGtDmBoPvHJoty5cn7ROZKZnGG6HGDSEADhCa3hdtncuJOFIgCGXOBxYfFKKUzLM10KMOkIgPCUmmCDbG56RZp6W02XAsAmStIK5fzic2Umx7fBQwiA8OyK4e3NrxEEAQ8rSs2X84rPkdlZM0yXAkw5AiA8jSAIeE9Bap6cV7Rc5mTNFJ/PZ7ocwAgCIEAQBDyhMDVPVhUtl7kEP4AACAxEEATcOdS7quhsOn7AAARAYBDHumv0OcP1oSbTpQAYo+kZpfrM3vKs6aZLAWyHAAgMob6nSXa17pWK7mrTpQAY4T5+87JnybmFS6U4rcB0OYBtEQCBEWgPd+ogeLDzqD5uDoD9Tu5YnDdflucvlpyULNPlALZHAARGIRTrld1tB2RP+0HOGgZsclbv2fmLZGn+QkkLpJouB3AMAiAwBrFEXHcDX2vdL22RDtPlAJ7cymVZ/iJZlDNXkvwB0+UAjkMABMaptqdB9rQdlKNd1ZIQhoeByeL3+fX8vmV5i6Qso9h0OYCjEQCBCdITC8n+jiOyp+2QdMeCpssBXCM7OVOW5C2QxbnzJT0pzXQ5gCsQAIEJpv5IHQvW6q5gVbBOLOGPGDCW1byzMqfpuX3lmdPZvw+YYARAYBJ1RYOyt/2Q7gyqDiGAoWUmZcjC3DmyJHcBq3mBSUQABKZAwkpIdbBeLxyp6KqWmBU3XRJgqy1c5mbPkkW582RGRindPmAKEACBKRaJR+VI1zEdBmt7Gk2XAxgzPaNEFubMlXnZ5ZISSDZdDuApBEDA8BDxwY4KHQbbI52mywEmXU5ylizKnau3b8lmiBcwhgAI2ERjqFkOdVbq7WRYRQy3reKdm12ut3ApTS8yXQ4AAiBgT02hFjnSVSVHu6qkI9pluhxgTJ0+NbQ7L6ecM3kBGyIAAjbX0tvWHwY5dQR2lpeSo7t8KvgVpuWbLgfAEAiAgIO0hzt1GKzsrpam3lb2GITxvfrUkO6szOkyJ3uGPp4NgDMQAAGH6o2HpTpYJ8e6a/UWM6F4r+mS4AHpgTS9QfOsrOn6OjWQYrokAGNAAARcQP0xbg63SVV3rT6FpDHUQncQE9blU3P4yrOm6xM5itIK2KcPcAECIODa7mC91ATrpS7UKB0RFpJgdHP5pmeUyrSMEr0xM+fvAu5DAAQ8QB1DV9fTqDeerg81SmuYxSR4Q35Krt6UeVpGqb4m8AHuRwAEPNohVIGw79ISbmfI2CP84pP81DwpSy8+EfoIfIAXEQABSDQRk+beVmnqbdGri9Ucws5ot+myMAFyk7OlOL1AitMKpSStUIrS8iXJn2S6LACGEQABDCocj+gwqENh6Ph1d6zHdFkYQmZSug56atFGSbq6LmSVLoBBEQABjFgo1itt4Q5pjXToa32JdOghZUydZH+Snren9t0rTM3T1wVpeZIWSDVdGgCHIAACmJBg2HoiDPYFQ3WEnVp8grFvv6I6etnJWZKbki35qbmSn5Kjr7OSM02XB8DhCIAAJk0sEdNzCTsj3fq6K9ot3dEefd0VDUokERUvS/En64Cnzs3NTjl+nZOcKTkpWTrkBXwB0yUCcCkCIACj8wyDsR7pifXqLqI6zUR1Dd/49fFr9bWTVimrodiMpHTJSEqTjEC6XmU72NfMzwNgCgEQgO2pv6bUPEPVMYwmovo6Eu/7dey022JWXBJWQodGdZ2w9K/0tf5afefE933iF7/Pp7tt6tqvv+67+I5fi1+vnFUdu5RA8vFrf7Ik669TJLX/18dvV78HAOyMAAgAAOAx/DMVAADAYwiAAAAAHkMABAAA8BgCIAAAgMcQAAEAADyGAAgAAOAxBEAAAACPIQACAAB4DAEQAADAYwiAAAAAHkMABAAA8BgCIAAAgMcQAAEAADyGAAgAAOAxBEAAAACPIQACAAB4DAEQAADAYwiAAAAAHkMABAAA8BgCIAAAgMcQAAEAADyGAAgAAOAxBEAAAACPIQACAAB4DAEQAADAYwiAAAAAHkMABAAA8BgCIAAAgMcQAAEAADyGAAgAAOAxBEAAAACPIQACAAB4DAEQAADAYwiAAAAAHkMABAAAEG/5/wFbUJqc+VJANAAAAABJRU5ErkJggg==",
      "text/plain": [
       "<Figure size 800x800 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Assuming the CSV is already loaded into a DataFrame called 'df'\n",
    "# If not, uncomment and adjust the line below to load your CSV\n",
    "# df = pd.read_csv('covid.csv')\n",
    "\n",
    "# Sample data based on the image (replace with actual data from your CSV)\n",
    "pre_existing_side_effect_data = {'Category': ['Yes', 'No'], 'Percentage': [24.3 ,75.7]}\n",
    "\n",
    "# Create a DataFrame\n",
    "df = pd.DataFrame(pre_existing_side_effect_data)\n",
    "\n",
    "# Create the pie chart\n",
    "fig, ax = plt.subplots(figsize=(8, 8))\n",
    "ax.pie(df['Percentage'], labels=df['Category'], autopct='%1.1f%%', colors=['#d4a373', '#98d7a5'], startangle=90)\n",
    "ax.axis('equal')  # Equal aspect ratio ensures that pie is drawn as a circle\n",
    "ax.set_title('pre_existing_skin_side_effect')\n",
    "\n",
    "# Display the plot\n",
    "plt.savefig(\"pier2.png\", dpi=300, bbox_inches='tight')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "bbc63f3e-efc9-40fb-a307-8836fee01612",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
